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ABSTRACT 
Current thinking by Traumatic Brain Injury (TBI) researchers and clinicians has devolved 
from the idea that TBI is an event with a finite recovery period, and have shifted to considering 
TBI a chronic disease with long-term implications for health. Therefore, there is great interest in 
determining acute biological and clinical factors that influence long-term health and function 
after injury. This interest drives the two central themes of this dissertation, to better understand: 
1) the continuum of TBI disability from acute to chronic recovery; 2) the effects of non-
neurological factors on recovery from TBI. Notably, the availability of data that spans the TBI 
disability continuum—from early stages post-injury to death—is sparse. Aim 1 of this 
dissertation explains a probabilistic marching procedure used to merge two databases, the 
National Trauma Databank and TBI Model Systems, which creates an infrastructure to examine 
the long-term effects of relevant acute care variables. In aim 2, the merged dataset is leveraged to 
assess the negative effects of acute care hospital-acquired pneumonia (HAP) on long-term global 
disability and health care utilization. HAP is one example of a non-neurological factor that 
impacts TBI recovery. Aim 3 focuses on two systemic markers of inflammation and hormone 
dysfunction, tumor necrosis factor-alpha (TNFα) and estradiol (E2), and assesses their inter-
relationship acutely after injury, and their temporal relationship to mortality. The public health 
implications of the work herein provide observational data to better understand the continuum of 
TBI disability, and major non-neurological contributors to recovery from injury.  
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1.0  INTRODUCTION 
1.1 TBI EPIDEMIOLOGY 
Each year, the Centers for Disease Control (CDC) estimates that 2.5 million Americans 
suffer a Traumatic Brain Injury (TBI) that results in either an emergency department (ED) visit, 
acute hospitalization or death.1 These estimates, however, do not account for individuals who do 
not receive medical attention for their injuries, or seek care in outpatient facilities. Many 
individuals with TBI are evaluated and released from an ED. However, individuals that suffer 
more severe injuries require hospitalization for their injuries. A subset of these individuals may 
go on to require care in a specialized brain injury rehabilitation program. An estimated 5.3 
million Americans, or 2% of the general population, live with chronic disability as a result of a 
TBI that required hospitalization.2 Among individuals hospitalized for TBI, 43.3% experience 1-
year disability, or symptoms directly related to their injuries that impair daily functioning.3  
The leading cause of TBI in the United States is falls, which account for roughly 35% of 
TBI, followed by motor vehicle accidents (17%), and strikes or blows to the head (17%).1,4 The 
major causes of TBI-related mortality are motor vehicle accidents, falls, and suicide.5 TBI can 
occur across the lifespan, and does not discriminate by age or sex. Infants and young children 
aged 0-4, as well as adolescents aged 15-19, and older adults over the age of 75 have the greatest 
frequency of ED visits from their injuries. However, those aged 75 and older have the greatest 
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burden of TBI-related hospitalizations, suggesting that injuries in this population are often 
complicated to treat, potentially due to co-morbid burden.4,6 Men are more likely than women to 
suffer a TBI;4 however, evidence is equivocal with regards to sex differences in TBI outcomes.7–
10 
The cost of TBI is considerable and warrants attention. The costs associated with 
prolonged disability is largely tied to loss of productivity; individuals with moderate-to-severe 
TBI often are unable to return to work or school. The per-patient lifetime cost of a moderate-to-
severe TBI is estimated to be over $100,000.11 Older individuals with TBI, though likely not 
having loss of vocational productivity costs like their working counterparts, represent a 
disproportionately higher economic burden compared to younger and middle-aged adults.12 Each 
year, 2 billion dollars is spent on healthcare costs for adults older than 65 with TBI.12,13 
1.2 TBI CLINICAL CARE CONTINUUM 
The recovery for patients with moderate-to-severe TBI is different than mild TBI, or 
concussion, where most patients return to pre-injury functioning within 3 months.14,15 For 
moderate-to-severe TBI, recovery from injury is long, and spans numerous phases. Acutely 
following injury, patients most often present to an ED and require an extended acute inpatient 
hospitalization. During this phase, patients are treated by clinicians in several departments, 
including trauma, critical care medicine, and neurosurgery. The priority at this time is acute 
clinical management in line with the Guidelines for the Management of Severe TBI, which may 
include: intracranial and cerebral perfusion pressure monitoring, decompression of mass lesions, 
seizure prophylaxis, management of systemic illnesses, blood pressure, and temperature.16  
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For acute survivors of TBI, the road to recovery continues with rehabilitation. The 
rehabilitation team includes: occupational therapists (OT), physical therapists (PT), nurses, social 
workers, neuropsychologists, and physiatrists. The inter-disciplinary rehabilitation team is 
focused on functional gains so patients can eventually re-assimilate into the community.17 The 
goal is not necessarily to make an individual exactly as they were before their injuries, but rather 
work with patients, and their family members, to identify their functional limitations, and find 
ways to adapt. Successful rehabilitation is usually measured by performance in activities of daily 
living, and eventually returning back to work or school and participating in community 
activities.18 
1.3 TBI RESEARCH CONTINUUM 
The long, extended care that exists clinically for patients with TBI may create a natural 
isolation between acute care and rehabilitation providers. In fact, in many hospitals, 
rehabilitation care is in an entirely different physical building than acute care. One downstream 
consequence of this schism is limited interaction between clinicians across the continuum. The 
implications are not limited to clinical care but can also trickle down to research. To date, 
clinical TBI research has been segmented; acute care research focuses on early factors that 
influence short-term survival and discharge disposition, and rehabilitation researchers pose 
research involving long-term disability and integration back to the community. Large databases, 
such as the National Trauma Databank and TBI Model Systems National Database, have moved 
the field in its understanding of components of the recovery course of moderate-to-severe TBI. 
However, there is a need to conduct more cross-cutting studies to bridge the gap between acute 
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and long-term factors to better understand the continuum of TBI-related disability from pre-
hospital factors all the way to death.  
1.4 TBI-RELATED DISABILITIES 
Individuals with TBI often have disorders of mood and behavior. Post-traumatic 
depression (PTD) is one of the most common complications after TBI, with prevalence rates 
ranging between 13-53.1% in the first year after TBI, a nearly 8-fold increased rate compared to 
the general population.19–23 Individuals with PTD more often endorse chronic functional 
impairment and psychosocial difficulties compared to individuals without PTD.24,25 In addition 
to PTD, individuals with TBI commonly suffer from behavioral dysfunction, which can manifest 
in problems of impulsivity, apathy, and personality changes. In instances of TBI with lesions to 
the frontal lobe,26 individuals present with executive and behavioral dysfunction.27 Overt 
behavioral changes represent the interplay between internal thoughts and feelings and the 
external environment, and are a component of a larger manifestation of emotional and cognitive 
changes that occur after severe TBI.28–30 Individuals with TBI with behavioral dysfunction have 
greater difficulty in assuming pre-injury life roles,31 and report more psychosocial 
difficulties.32,33  
Patients with moderate-to-severe TBI also manifest with chronic cognitive impairment. 
In fact, cognitive deficits after TBI are among the most common symptoms, with roughly 70% of 
severely injured patients experiencing substantial cognitive deficits across multiple domains.34 
One case-control study compared patients with TBI to trauma patients without brain injuries, and 
found that patients with TBI had greater deficits in the domains of: attention, information 
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processing, reaction time, memory and learning, verbal fluency, and mental flexibility.35 The 
location of focal brain lesions are a major contributor to the specific domains of cognition that 
are impaired. For example, one study of penetrating TBI determined that lesions of the left 
hemisphere were associated with poor vocabulary performance, and lesions to the right 
hemisphere were associated with visuospatial deficits.36 It is also well understood that focal 
lesions to the frontal lobe are closely linked to deficits in executive functioning, like planning 
and task completion.27 White matter disruption, which occurs most often in the setting of axonal 
injury, is also associated with cognitive impairment.37 Other studies have shown that dysfunction 
in dopamine (DA) pathways,38,39 and variability in DA genes, are linked with cognitive 
impairment across multiple domains.40 Cognitive impairments in patients with TBI are extremely 
common and are important considerations for brain injury clinicians because it affects 
rehabilitation planning41 and are a primary indicator of the ability to return to work.31 
Evidence from observational studies conducted in the last few decades suggests that most 
individuals with moderate-to-severe TBI take months to years to recover, and a majority of 
patients never fully return to pre-injury functioning and live with chronic disability.42,43 As stated 
above, rehabilitation clinicians focus on improving function for patients with TBI and working 
towards community integration, which includes: independence in activities of daily living (e.g. 
toileting, personal care, feeding)44 and transportation,45 return to work or school,46–48 and 
maintenance of productive social relationships.49 The latter, maintenance of productive social 
relationships, has been reported by patients in focus groups as the single most important factor 
that they personally characterize as “successful” integration into the community.50 Research in 
TBI is moving towards an integration and partnership between basic science, clinical researchers, 
and policy makers to improve functioning for TBI survivors.51 This research focus aligns well 
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with the International Classification of Functioning, Disability and Health (ICF)52 framework, 
which defines functioning and disability as more than just a biomedical construct focused on 
disease, but rather as a multidimensional concept, relating to dynamic interaction of “body 
functions and structures, activities, participation, and environmental factors.” This framework 
also is the cardinal basis of the Rehabilomics model of Rehabilitation research that has been 
pioneered by committee member, Dr. Amy Wagner.53–55 My charge as a TBI epidemiologist is to 
integrate these principles into my dissertation research, appreciating that the end goal is to 
understand how early biological factors interface and influence long-term health and functioning 
among individuals living with TBI.  
1.5 TBI BIOLOGY: ACUTE TO CHRONIC PATHOPHYSIOLOGY 
TBI can be broadly characterized by a primary insult and subsequent secondary injury 
cascade. The primary insult may be the result of focal or diffuse damage. Focal injuries are 
characterized by contusions, intracranial or extra-axial hemorrhages. Diffuse damage results 
from axonal stretch injuries, most commonly resulting from rapid acceleration/deceleration 
forces. Following primary injuries, there is a secondary injury biological cascade that evolves in 
the months to years following incident injury. Beyond the structural brain damage associated 
with TBI, the components of the secondary injury response to brain injury are complicated and 
can be broadly grouped into a humoral triad, which involves neurotrophic, endocrine, and 
immunological networks that each have independent functions, but also possess the capacity for 
cross-talk via multiple signaling pathways that contribute to homeostatic regulation. Acute 
dysfunction in components of the humoral triad may eventually lead to chronic disruption. 
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Chronic pathology to these humoral signaling systems is, at least in part, the biological basis of 
why TBI is considered a biological aging accelerator, which may lead to premature 
neurodegenerative disease, as well as increased risk for chronic health conditions, such as 
epilepsy, depression, and suicide. 
1.6 TBI BIOLOGY: A HUMORAL TRIAD 
 There have been several clinical observational studies characterizing acute disturbances 
to the humoral triad after severe TBI. Existing studies also examined how variability in acute 
biomarkers in the brain and periphery are associated with recovery from injury across 
multidimensional outcomes. Fewer studies, however, have integrated multiple humoral signaling 
systems into their assessment to understand how these are connected. 
1.6.1 Neurotrophins 
A family of proteins known as neurotrophins is one component of the humoral triad that 
promotes survival, development, maintenance and function of neurons. Following TBI, an 
extensively studied biomarker in the neurotrophic family is brain-derived neurotrophic factor 
(BDNF), the systemic levels of which are initially reduced in the periphery, but modestly 
increased in the brain after TBI.56 Clinical studies demonstrate BDNF genetics and levels are 
associated with mortality, with nuanced effect modification observed across the lifespan of 
patients; the biological actions of BDNF in older adults differs compared to their younger 
counterparts.56,57 The hippocampus is a brain region that is particularly vulnerable, with focal 
8 
depression of BDNF expression, and genetic variation in the BDNF gene is associated with 
hippocampal volume after TBI.58 
1.6.2 Endocrine System 
A second component of the humoral triad is the endocrine system. In the setting of TBI, 
pituitary dysfunction may result in several clinical conditions, known as neuroendocrine 
dysfunction.59–63 Signaling abnormalities may be due to direct or indirect damage to the 
hypothalamus or pituitary, which impacts functioning of the hypothalamus-pituitary-adrenal 
(HPA) or hypothalamus-pituitary-gonadal axis (HPG) axes. TBI also induces an acute stress 
response that increases endogenous cortisol production.64 The beneficial and detrimental effects 
of cortisol elevations are an exemplar of the existence of cross-talk among the humoral triad 
network, as cortisol can act as a significant mediator of dysfunction in both neuroinflammation65 
and BDNF expression.66 Also, in pre-menopausal women, chronically elevated cortisol can 
contribute to amenorrhea and menstrual cycle dysfunction,67 and acute increases in cortisol are 
associated with long-term cognitive impairments.68  
The effects of pituitary dysfunction extend beyond elevations in cortisol and include 
disruptions to the HPG axis. Men experience a period of hypogonadotropic hypogonadism (low 
testosterone and low luteinizing hormone) that for some resolve after 8-12 weeks post-TBI, but 
for others, may extend for several months after injury and lead to poorer functional outcomes.69 
A series of clinical observational studies, led by committee member Dr. Amy Wagner, also show 
that the steroidogenesis pathway is acutely disturbed following TBI. The downstream 
consequence of acute dysfunction of the HPG axis is dysregulation in sex hormone products in 
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the gonads, known as secondary hypogonadism. As portrayed in Figure 1, through damage to 
the hypothalamus and/or pituitary, the negative feedback mechanisms are dysfunctional. 
 
Figure 1. HPG Axis Dysfunction Leads to Secondary Hypogonadism after Severe TBI 
1.6.3 Acute Inflammation 
The third component of the humoral triad is the post-traumatic inflammatory response. 
Acute inflammation after TBI is characterized by an aggressive innate immune response, the 
body’s “first-line” defense response to injury.70 The neuroimmune response is largely mediated 
by microglia, which are resident central nervous system (CNS) immune cells that rapidly change 
from a resting to an activated state upon surveillance and detection of CNS damage, like that 
seen from TBI.71,72 Activated microglia facilitate inflammation by recruiting pro-inflammatory 
cytokines, chemokines, and cell-adhesion molecules to injury sites to clear debris and dead 
neural tissues and cells.73 There have been several recent studies characterizing acute 
inflammatory markers in the brain and periphery. In a previous study I co-authored,74 
“inflammatory clusters” of individuals with severe TBI were obtained from a principal 
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components analysis of CSF inflammatory cells. It was determined that ~30% of individuals fell 
into a “pro-inflammatory” cluster, which tended to include older individuals that 
overwhelmingly had poorer global outcomes compared to those in another cluster with an 
average-to-below average inflammatory load. Interestingly, in the same study we determined that 
individuals in the “pro-inflammatory” cluster had increased levels of CSF hormones (cortisol, 
progesterone, E2, testosterone) and CSF BDNF, in addition to serum cortisol and BDNF, further 
supporting the inter-relationship observed between biomarkers within the humoral triad.74   
The negative consequences of excessive neuroinflammation on complicating conditions 
and multidimensional outcomes following TBI are becoming increasingly apparent from several 
recent clinical studies from our group. One study found that higher CSF concentrations of 
interleukin-6 (IL-6), a major pro-inflammatory cytokine, in the first week are associated with 
poor global disability in the first year.75 Another study found that interleukin-1β levels and 
genetic variability in the interleukin-1β gene influences IL-1β levels and increases risk for 
seizures after TBI.76 Other studies determined that acute inflammatory markers in the 
cerebrospinal fluid are associated with depression risk77 and risk for suicidal ideation and 
impulsive behavior.78  
1.6.4 Chronic TBI Inflammation 
Acute homeostatic disturbances following TBI can extend beyond the first week into a 
subacute and chronic period after injury. The acute innate inflammatory cascade is considered a 
crucial component in the healing process; however, persistent inflammation over long periods 
can be affect healthy tissue.79 Generally, the beneficial effects of inflammation are derived when 
these processes are under tight physiological control; uninhibited levels seem to be 
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counterproductive to recovery from TBI.80 This complexity is why some in the field coin post-
traumatic inflammation as a “double-edged sword.”  
An effective illustration of complex signaling effects associated with inflammation can 
be gleaned from studying the marker IL-6, which can undergo either classical signaling or trans-
signaling depending on the binding patterns of IL-6 to its membrane-bound receptor (classical) 
or soluble receptor (trans). The former, classical signaling, leads to an anti-inflammatory 
cascade, and the latter, trans-signaling, can cause chronic inflammation.81,82 Our preliminary 
work suggests that higher IL-6 soluble receptor signaling during the subacute phase after TBI 
does have a negative effect on global outcome83 and its negative effects on outcome are mediated 
by post-acute cortisol levels.84  
Recent observational studies have examined chronic immunological disturbances after 
severe TBI. A landmark study by Ramlackhansingh et al.85 determined that individuals with TBI 
have microglial activation in subcortical regions of the brain present several years after injury, 
and activated microglia in the thalamus is associated with cognitive impairments. Another study, 
which I co-authored, showed that chronic inflammation in the serum was present in the first year 
after TBI, and increased inflammatory load in the first three months was associated with poorer 
global outcomes at 6 and 12 months after injury.86   
1.7 UNDERSTANDING BRAIN-TO-BODY CONNECTIONS AND SYSTEMIC 
CONTRIBUTORS TO IMMUNITY 
Despite TBI being a primary injury to the brain, inflammatory processes are not confined 
to the CNS. After injury, inflammatory cells from the periphery cross a damaged blood brain 
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barrier (BBB) to aid in brain tissue repair.70 Among individuals that sustain polytrauma, or 
concurrent traumatic injuries to multiple regions of the body, peripheral immune markers are 
recruited to aid in repair of bodily injuries.75 Further, the brain and the peripheral immune system 
communicate via the autonomic nervous system (ANS).87,88 In response to acute injury, like TBI, 
two main “stress” pathways are activated: the SNS and the HPA axis.87 SNS activation follows a 
release of sympathetic neurotransmitters, including norepinephrine (NE), which has direct effects 
as a neuromodulator in lymphoid organs that supports cytokine production,87,89 and also 
facilitates an acute phase hepatic response, producing pro-inflammatory cytokines like tumor 
necrosis factor-α (TNFα).  
Peripheral contributors to immunity can be highlighted by TNFα, a pleiotropic pro-
inflammatory marker, and one of the most extensively studied inflammatory proteins in the field 
of immunology.90–92 The relevance of TNFα extends beyond its pro-inflammatory properties. 
Specifically, TNFα in the adipose is a transcription factor for the expression of the aromatase 
gene, located in promotor region I.4.93–95 The result of aromatase expression at this site is an 
increase in extra-gonadal production of E2, which is a known mortality marker.96 Specifically, 
E2 acts as a potent vasodilator by promoting nitric oxide and hydrogen sulfide pathways.97–100 It 
is possible that a propagation of vasodilation of the vasculature, mediated by E2 and TNFα, 
could lead to non-neurological organ dysfunction. That is, individuals with TBI suffer a 
significant compromise to another body system besides the brain. The concept of non-
neurological organ dysfunction has been proposed in the setting of neurocritical care.101,102 
Zygun and colleagues101 determined that, in a cohort of severe TBI, roughly 1 in 3 patients 
develop some form of non-brain organ failure during their hospital stay. Respiratory failure 
occurred in nearly 1 in 4 patients and cardiovascular failure occurred in nearly 1 in 5 patients.101 
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In the same study, Zygun101 determined that individuals with the non-neurological organ failure 
had a 63% increase in their odds for mortality and 53% increase in odds of poor Glasgow 
Outcome Scale (GOS) scores during their hospitalization, compared to their counterparts without 
non-neurological organ dysfunction. Similarly, another study by Kemp and colleagues102 
determined that approximately non-neurological organ dysfunction accounts for 2/3 of all deaths 
after severe TBI.  
Systemic infection is another non-neurological factor, commonly co-occurring with TBI, 
which can propagate systemic inflammation. Patients with TBI are particularly at risk for 
pulmonary infections stemming from prolonged periods of mechanical ventilation and long 
hospital lengths of stays. Immediately following injury, some individuals also experience a 
trauma-induced suppression in lymphocyte production, known as lymphopenia. The result is a 
decreased capacity to fight new pathogens, and an increased risk for opportunistic infections. 
Several studies have explored the harmful effects of lymphopenia in trauma populations.103–107 
One study found that individuals with persistent lymphopenia after the first four days of trauma 
had a 2.5 times increased risk of death compared to those with normal leukocyte levels.106 Work 
that I have been actively involved with has collected preliminary data observing lymphopenia in 
a population of n=273 with severe TBI. In Figure 2, the lower lymphocyte trajectory 1 (seen in 
blue) has lymphocyte counts below the lower range for lymphocyte levels for an extended period 
in the first week after injury. In this cohort, those in the low trajectory group had an 65.9% rate 
of HAP versus 51.0% in the high trajectory (χ2=5.0, p=0.026).  
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Figure 2. Mean Lymphocyte Levels by Lymphocyte Trajectory Group 
1.8 SPECIFIC AIMS 
 The two central themes of this dissertation are to better understand: 1) the continuum 
of TBI disability from acute to chronic stages of recovery; 2) the effects of non-neurological 
factors on recovery from TBI. 
1.8.1 Aim 1: Applications of Probabilistic Matching 
Aim 1 details the specific statistical methodology of a probabilistic algorithm used to 
merge two large databases, the NTDB and the TBIMS National Database. The purpose of 
this merger is to address a major gap in TBI research: the lack of research across the continuum 
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of TBI disability, from early to late stages in the injury progression. The methodology employed 
is probabilistic matching, which relies on the creation of weights based on common data 
elements between two deidentified databases. Because patients were not co-registered in both 
databases, the two databases can only be merged through probabilistic techniques. To test the 
validity metrics of the probabilistic algorithm, we utilized a concurrent deterministic linkage that 
served as a gold standard. In the discussion and public health relevance sections of this 
dissertation, I explain the implications of creating a database infrastructure that sets the stage for 
future studies that can longitudinally study the effect of early factors on long-term measures of 
disability. 
1.8.2 Aim 2: Effects of HAP 
Aim 2 of this dissertation aims to examine the long-term impact of HAP on global 
outcomes in a large, multi-center population with moderate-to-severe TBI. The reason why 
patients with TBI are particularly at risk for pneumonia is multi-factorial, including prolonged 
ventilation, long hospital lengths of stay, exposure to nosocomial pathogens, and acute 
immunosuppression leading to trauma-induced lymphopenia. Much of the prior TBI literature 
that has examined the effects of HAP have focused on: 1) the costs of incident infection,108 and 
2) the effects on in-hospital outcomes (e.g. short-term survival and outcomes).109–112 Two small
prior studies show preliminary evidence of the negative long-term consequences of HAP on 
recovery from TBI, though this remains a relatively under-studied area.113,114 The biological 
plausibility for the negative long-term effects of pneumonia post-TBI may seem elusive at first, 
especially if an infection is treated and cleared soon after the onset of illness. However, the 
rationale is grounded in the theory that early infection elicits a systemic inflammatory response, 
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which adds to an already considerable inflammatory response from the primary TBI, thus 
priming the body for a chronic inflammatory milieu. This hypothesis is supported by data that 
individuals with a greater number of acute hospital complications had a greater chronic 
inflammatory load 2 weeks to 3 months following severe TBI.86  
1.8.3 Aim 3: Effects of E2 and TNFα 
 Aim 3 of this dissertation is to examine inter-relationships between E2 and TNFα 
in two time epochs over the first five days after TBI, and its effects on mortality risk in the 
first six months after TBI. A previous study by Wagner and colleagues96 determined that acute 
peripheral E2 is associated with mortality; however, the mechanism by which E2 affects 
mortality risk is still not clear. TNFα is a potent vasodilator and a critical molecule involved with 
septic shock in other ICU populations.90,94,115–117 Because TNFα is involved in E2 
transcription,118–120 it may explain in part the observed E2 mortality risk. Additionally, increasing 
E2 has a positive feedback signaling effect that contributes to exaggerated levels of 
inflammation.87,121 The potentially lethal cycle of excess E2 and TNFα has not been established 
to date in the TBI field; therefore, will be a focus in the third chapter of this dissertation.    
1.9 INTEGRATIVE SUMMARY OF DISSERTATION 
Individuals with TBI have heterogeneous pathological responses and clinical exposures 
immediately after their injury that has direct causal implications for long-term recovery. 
Considering the literature reviewed, a conceptual figure integrating the three aims of this 
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dissertation is presented in Figure 2. Complex brain-body relationships, including cross-talk 
between the brain and periphery from SNS activation and BBB disruption. This dissertation 
builds upon my previous research in the field of TBI, focusing on key elements of TBI recovery: 
acute infection, inflammation, and hormone dysfunction. I also discuss the procedures involved, 
and implications, of bridging two large databases within trauma and rehabilitation to build an 
infrastructure spanning the continuum of TBI disability. 
Figure 3. Kumar Dissertation Conceptual Model 
The effects of TBI span the brain and periphery. Elements of brain pathology represented include an induction of the stress 
response, which includes the Hypothalamus-Pituitary-Adrenal (HPA) axis and sympathetic nervous system (SNS) outflow. Blood 
brain barrier disruption is also portrayed, which is one source of communication between the brain and periphery. Aim 2 focuses 
on nosocomial pneumonia after TBI, which may be caused by prolonged mechanical ventilation on top of a trauma-induced state 
of lymphopenia. It is believed that acute pneumonia after TBI contributes to a chronic inflammatory state that increases risk for 
poor long-term outcomes. Aim 3, shown in the periphery, involves nuanced relations between estradiol (E2) and TNFα. 
Peripheral sources of TNFα include from the liver through a sympathetic nervous system-initiated acute phase response. TNFα 
importantly aids in extra-gonadal production of E2 in adipose tissue. The negative effects of excessive E2 and TNFα is 
vasodilation of systemic vasculature, which may contribute to non-neurological organ dysfunction and mortality. 
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2.0  AIM 1: PROBABILISTIC MATCHING OF DEIDENTIFIED DATA FROM A 
TRAUMA REGISTRY AND A TRAUMATIC BRAIN INJURY MODEL SYSTEM 
CENTER: A FOLLOW-UP VALIDATION STUDY  
2.1 ABSTRACT 
In a previous study, individuals from a single Traumatic Brain Injury Model Systems 
(TBIMS) site and trauma center were matched using a novel probabilistic matching algorithm.  
The TBIMS is a multicenter prospective cohort study containing >14,000 participants with TBI, 
following them from inpatient rehabilitation to the community over the remainder of their 
lifetime. The National Trauma Databank (NTDB) is the largest aggregation of trauma data in the 
United States, including over 6 million records. Linking these two databases offers a broad range 
of opportunities to explore research questions not otherwise possible. Our objective was to refine 
and validate the previous protocol at another independent center. An algorithm generation and 
validation dataset were created, and potential matches were blocked by age, sex, and year of 
injury; total probabilistic weight was calculated based on 12 common data fields. Validity 
metrics were calculated using a minimum probabilistic weight of 3. The positive predictive value 
was 98.2% and 97.4% and sensitivity was 74.1% and 76.3%, in the algorithm generation and 
validation set, respectively. These metrics were similar to the previous study. Future work will 
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apply the refined probabilistic matching algorithm to the TBIMS and NTDB to generate a 
merged dataset for clinical TBI research utilization. 
2.2 INTRODUCTION 
Database linkage is a powerful statistical methodology that can be leveraged to answer 
important questions in the field of medicine that are not possible in either dataset alone. In 
instances where unique identifiers (e.g. medical record numbers) are available, deterministic 
linkage offers a quick and efficient way to link records between databases. However, many 
publicly available datasets are de-identified for privacy reasons, making record linkage a more 
computationally challenging endeavor. Probabilistic linkage, which relies on the matching values 
of common data elements between databases, can be implemented in such instances without the 
need for unique identifiers.122   
Clinical care of patients with moderate to severe TBI occurs along a continuum, 
beginning with emergency room care and acute inpatient hospitalization at a trauma center. After 
discharge from the acute hospital, many patients also require comprehensive inpatient 
rehabilitative services prior to integration into the community. Most of the research conducted to 
date in TBI has been divided, either: 1) exploring the effect of acute care trauma factors on 
hospital-based outcomes, or 2) examining long-term recovery in the chronic stages of TBI, 
beginning during inpatient rehabilitation and extending months to years after TBI. Very few 
research studies have bridged these two avenues of research to explore the long-term effects of 
acute care trauma factors, largely because of a lack of available data across these two fields to 
address these cross-disciplinary types of research questions. Linking the NTDB and TBIMS 
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offers the unique opportunity of simultaneously access both the largest acute trauma care 
database in the world (NTDB) and the largest longitudinal TBI outcomes National Database, the 
TBIMS, which follows patients for the entirety of life post-injury. 
In a previous report, we developed a novel probabilistic matching algorithm at a single 
medical center to link two databases, the Traumatic Brain Injury Model Systems (TBIMS) single 
site to trauma registry data records submitted to the National Trauma Databank (NTDB).123 A 
parallel deterministic linkage was possible due to available medical record numbers, allowing for 
us to derive a true match status. Thus, validity metrics were calculated based on 
concordance/discordance between linked matches from the probabilistic matching algorithm and 
true match status from the deterministic linkage. Correspondingly, an increased emphasis was 
placed on two specific metrics in the probabilistic matching algorithm: positive predictive value 
(PPV) and sensitivity. In this context, PPV is defined as the proportion of individuals linked in 
our probabilistic algorithm between databases that, in reality, are the same individual.  
Sensitivity is the proportion of individuals that are true matches between the two datasets that are 
linked using the probabilistic algorithm. In a previous single site study applying our algorithm, 
we achieved a PPV of 99% in both an algorithm generation and validation subset; and a 
sensitivity of 88% and 83% in these algorithm generation and validation subsets, respectively.123  
This initial result is important in that it indicates the accuracy and validity of the proposed 
probabilistic matching algorithm, in which more than 80% of target cases were matched, and 
almost 99% of matched cases were the same individual. 
As a next step of evaluating the veracity of this probabilistic matching protocol, the 
purpose of the present study is to apply and validate this novel probabilistic algorithm in another, 
independent single medical center TBIMS dataset and trauma registry records. This validation is 
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technically possible because of the availability of true match status between the two datasets for 
all patients. Therefore, in this follow-up study, we conducted a parallel deterministic linkage to 
allow for calculations of algorithm validity metrics. Having the algorithm validated in an 
independent center will add a greater level of veracity and confidence to the protocol, with a 
long-term goal of this project to have a refined and validated probabilistic algorithm that can be 
applied to the TBIMS National Database and NTDB on a national scale.   
2.3 METHODS AND MATERIALS 
2.3.1 Probabilistic linkage 
This study was approved by the local institutional review board. Background of the 
mechanics of the probabilistic linkage method applied to TBIMS and trauma dataset in previous 
single-site study has been described in great detail elsewhere.123 Briefly, for each matched pair, 
agreement for each linking variable was evaluated in the algorithm by assigning a weight for 
each corresponding variable. The total weight was summed over all matching variables. The 
higher the total weight, the greater the probability that the matched pair in reality belongs to the 
same person. When deciding whether or not cases are considered linked between the two 
datasets, three tiers of criteria were examined and checked for validity metrics, with each 
increasing tier having more stringent criteria for matching. 
To estimate the matching weight, we applied two commonly used criteria: the quality of 
the data and the probability of random agreement. The quality of data metric is described by m, 
or the probability of matched pair agreement on a given linking variable within each value of the 
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variable in the trauma dataset, given the pair is a true match. For example, if 90% of the matched 
pairs agree on systolic blood pressure (SBP) when SBP is 140 in trauma, then m=0.9.  For a 
matched pair in this example that does not agree on SBP at 140, then m=0.1. The probability of 
random agreement is defined by u, which estimates the probability that a matched pair will 
randomly have the same value for a given linking variable. U is determined by the frequency 
distribution of each linking variable. For instance, while the probability of a matching pair 
randomly matching on sex is 50%, the probability of randomly matching on same birthday will 
be 0.27% (1/365).122 
2.3.2 Matching blocking 
To increase the efficiency of matching, blocking was employed using the variables: age, 
sex and year of injury. Only individuals in each database with exact value matches for these 
three variables were included in the probabilistic match. Blocking can be regarded as a filter 
process to remove matching pairs that are highly unlikely to be the true match.124  This step is 
crucial in reducing the computational load of the matching procedure. Age, sex and injury year 
were applied in the previous study123 and we observed a low likelihood of human data entry 
error, resulting in a high specificity. 
2.3.3 Linking variables and weight estimation 
After blocking procedures were complete, the following variables were selected in the 
probabilistic matching: acute care length of stay, initial Glasgow Coma Scale (GCS) motor, 
verbal, eye movement, total (sum of the previous three GCS sub-scores), race, respiratory rate 
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and initial systolic blood pressure in the emergency department, head injury pattern (fracture of 
base of skull or fracture of calvarium), cause of injury and acute care health insurance payer 
information. When compared with the probabilistic linkage algorithm we used in the previous 
study123, we excluded four binary matching variables: intubation status, sedated status and spinal 
injury status (SCI) in the current study due to: 1) poor data quality (m<0.7), 2) low 
differentiation between deterministic true and false matches, and 3) very little appreciable 
improvement in overall sensitivity or PPV. Of note, the binary variables with high m values 
(>0.7) were included (cranial surgery and skull based fracture) as they were deemed very high 
quality data to use for the purposes of matching. 
Since the true match status was known through medical record numbers, m was 
calculated from the probability of agreement for true matches.  The value of u was estimated 
from the frequency distribution for each linking variable in the trauma registry, the larger of the 
two datasets.  The weight for each matched pair on each linking variable (wij) was assigned if the 
pair agreed on the matching variable: 
Wij = log (mij / uij) 
where i was the ith linking variable and j was the jth matching pair.   
Also, the following weight was assigned if the pair disagreed on the matching variable by: 
Wij = log [(1-mij) / (1-uij)] 
where i was the ith linking variable and j was the jth matching pair.   
Total weight was the sum of the weight for each matching variable. In probabilistic linkage, 
there is a characteristic bimodal distribution of weights: one large distribution reflecting weights 
of comparisons that are primarily disagreeing negative weights (left distribution), and another, 
smaller distribution, reflecting comparisons that primarily agree and have mostly positive 
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weights (right distribution). Of note, it is common to have some small overlap between the left 
and right distributions. 
2.3.4 Clustering and cluster weight difference 
For each case in the TBIMS dataset, multiple cases within the trauma registry are 
“potential matches” contingent on sharing the same age, sex and injury year as the TBIMS case.  
This group of “potential matches” is called a cluster.  Within each cluster, the matched pair with 
the highest total weight is regarded as the most probable match. Occasionally, however, the total 
weights between two independent potential matches can be very similar. For example, a matched 
pair theoretically could differ with each other by only one or two matching variables. The cluster 
weight difference (CWD) was introduced as a quantitative measure of this issue. CWD was 
computed as the difference of the highest total weight to the second highest total weight within 
each cluster. If CWD was less than the chosen threshold value, all matched pairs within that 
cluster were rejected because of the difficulty in distinguishing within a certain margin of error 
which pair is the true match. Similar to our previous probabilistic matching algorithm123, we 
applied threshold values for CWD that corresponded to the 90th percentile of CWD for false 
matching. 
For this validation study, validity metrics were calculated and assigned to one of three 
“tiers”, which designate from more liberal to more stringent criteria (hereafter refer to Tier I-III) 
for considering cases to be linked between datasets (see detailed schematic representation in 
Figure 4).   
 Tier I: the greatest weight in each cluster is considered the linked match;  
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Tier II: met criteria for Tier I, and the total weight value that corresponds to the 
 right tail of the overlapping distribution of weights; 
Tier III: met criteria for Tier II, and CWD greater than 90th percentile CWD for 
 false matches 
 
Figure 4. Schematic representation of determining probabilistic linkage by using progressively 
stringent criteria (Tier I-III) 
 
 
We considered the Tier III criteria to be the most stringent and most conservative criteria 
because of the added consideration of a margin of error. It is possible that two cases in the 
trauma database have similarly large weights. That is, there is a strong agreement in values of 
several matching variables, and in such a case, the CWD is small, making it harder to correctly 
identify the true match. A scatter plot was generated of weight by CWD, stratified by true and 
false match status, with lines overlaying the Tier II and III cut points.  We expected that 
individuals meeting both Tier II and III criteria (top right quadrant of scatterplot) will be mostly 
true positives. 
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2.4 RESULTS 
To generate the probabilistic matching algorithm and validate it, a random number was 
generated from the uniform distribution on the interval between 0 and 1 for each subject in the 
TBIMS set. A threshold of 0.5 was applied to randomly divide the dataset into training and 
validation set. The final datasets contained 497 and 544 cases in the training and validation set, 
respectively. After blocking individuals in each database on age, sex and injury year, we 
obtained 4,428 matched pairs for the training set and 4,743 pairs for validation set.   
With 440 TBIMS rehabilitation cases in the matched pair training set, a total of 4,429 
comparisons were obtained from a trauma dataset that contained 12,942 trauma cases. Using Tier 
I criteria, the sensitivity was 82.3% (Table 1). Based on a visual inspection of the frequency 
distribution in the training set stratified by greatest weight per cluster vs. all other weights in the 
cluster, the weight threshold was set to 3 (Figure 5). Using this Tier II criteria threshold, 
sensitivity was at 74.1% and positive predictive value (PPV) was 98.2% if the highest weight of 
each cluster was considered a positive match. The 90th percentile of CWD (7.0) for false 
matches was used as our threshold for CWD in both the training and validation datasets 
(Supplemental Table S1). Using the added Tier III criteria of CWD of 7.0, sensitivity and PPV 
were 66.6% and 99.3%, respectively (Table 2).   
For the validation set, a total of 485 TBIMS rehabilitation cases and 12,942 trauma cases 
were used to form a 4,744 matched pair validation set using the same blocking procedure.  Using 
Tier I criteria, sensitivity was 84.1% (Table 1). Applying the same Tier II threshold cutoff for 
weight of 3 as the training set, sensitivity was 76.3% and PPV was 97.4%.  When a further Tier 
III criteria of CWD greater than 7 subsequently was applied (as derived from the training set), 
sensitivity and PPV were 70.7% and 98.0%, respectively (Table 2).   
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Figure 5. Frequency distribution of weights.  
Panel (A) is the training set, and panel (B) represents the validation set. The frequency distribution of weights 
among those with the greatest weight in the cluster (dark gray), compared to other weights within cluster (light 
gray). A cluster is defined as all the trauma cases that are compared to a simple TBI-MS case, after blocking for age, 
sex, and year of injury. The vertical line represents the Tier II criteria of weights greater than 3. 
 
 
 
 
Table 1. Descriptive characteristics of algorithm generation and validation subset 
 Trauma Rehab Total 
comparisons 
Mean cases 
per cluster 
No. of 
rehab cases 
did not 
block to 
true match 
True match 
with top 
weight in 
cluster (%) 
(TIER I 
criteria) 
Training set 12,942 440 4,429 8.9 57 408 (82.3) 
Validation set 12,942 485 4,744 8.8 59 455 (84.1) 
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Table 2. True match status by probabilistic linkage status in training set 
 Training set  Validation set 
 True match status Total  True match status Total Link status True  False   True  False  
A        
  Link 326 6 332  370 10 380 
  Nonlink 114 3,983 4,097  115 4,249 4,364 
  Total 440 3,989 4,429  485 4,259 4,744 
  Sensitivity 74.1%  76.3% 
  PPV 98.2%  97.4% 
B        
  Link 293 2 295  343 7 350 
  Nonlink 147 3,987 4,134  142 4,252 4,394 
  Total 440 3,989 4,429  485 4,259 4,744 
  Sensitivity 66.6%  70.7% 
  PPV 99.3%  98.0% 
A. Cases with highest weight in cluster greater than 3 (TIER II criteria) 
B. Adding as an exclusion criteria a CWD>7 in addition to A (TIER III criteria) 
 
For the training and validation dataset, a scatterplot was generated of the total weight by 
CWD, with a vertical and horizontal line overlaid to depict the Tier II (weight=3) and Tier III 
(CWD=7) cut points, respectively (Figure 6). The true and false matching status is shown, with 
the top right quadrant representing individuals meeting both Tier II and III criteria. As expected, 
a majority of individuals in the top right quadrant are true positives in the training and validation 
datasets. 
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Figure 6. CWD and Weight by Matching Status.  
Panel (A) is the training set, and panel (B) represents the validation set. The case weight difference (CWD) by 
weight. The vertical line represents the Tier II criteria of weights greater than 3. Horizontal reference line represents 
the chose Tier III cutoff at 5.4. The four symbols: square, triangle, plus, and circle, correspond to the true positive, 
true negative, false positive, and false negatives when comparing the results of the probabilistic linkage algorithm to 
the gold standard deterministic linkage 
 
To assess for potential selection bias in the demographics of matched vs. unmatched 
individuals, selected blocking and matching fields were examined by Tier II criteria 
(Supplemental Table S2). Our data indicated that blocking and matching fields largely did not 
significantly differ between matched and unmatched cases except for age and LOS in the training 
set and SBP in the validation set, suggesting a low likelihood of selection bias. 
2.5 DISCUSSION 
The aim of the present study was to refine and validate a probabilistic matching algorithm 
to link data from the TBIMS to the trauma records from a single clinical site that submits data to 
the NTDB. In this study, we executed a similar probabilistic procedure in an independent health 
system where true match status is known, allowing for the calculations of algorithm validity 
metrics. Importantly, any given dataset and patient population in a single site may differ from 
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another single site in another region, the metrics and threshold values are subject to some degree 
of fluctuation. Specifically, the derivation of the m and u values are a function of the data quality 
and frequency distribution of values in a specific dataset. Validation in an independent site thus 
is a crucial step to refine our novel probabilistic algorithm before full implementation in a 
scenario where true match status is unknown. 
The probabilistic algorithm used in the original study was modified by omitting three 
binary variables, including intubation status, sedated status and spinal cord injury (SCI) status.  
In instances where the quality of the data is determined to be poor (m<0.7), the probability that 
the value for a binary variable will match between datasets by chance alone will be increased. 
Therefore, we made the determination to set the u value to 0.5 to correct for uneven distributions 
on the likelihood of 0 or 1, and base the score of the weight of binary variables on the data 
quality. For binary variables with a moderate to high data quality (M value is at least greater than 
0.7 for both levels), we still retained binary variables in the matching algorithm such as cranial 
surgery and skull base fracture. To compensate for inflation of U due to skewed distribution, we 
set any U above 0.5 to 0.5, and thus, made U irrelevant in the total weight computation. 
Though binary variables were removed from the prior probabilistic algorithm, it is 
important to note that no new variables were added into the algorithm. Given the fact that we 
refined the algorithm, we derived a training and validation set in the present study. In the training 
set, using tier II criteria of a weight greater than 3, we achieved a PPV of 98.2% and sensitivity 
of 74.1%; and in the validation set a PPV of 97.4% and sensitivity of 76.3%. These results are 
roughly in line with the metrics obtained in the prior study.123 In probabilistic matching having 
utmost confidence that cases that are claimed to be linked by the algorithm are in fact true 
matches, the definition of PPV, is the most important validity metric. In lay terms, since we 
31 
know it is impossible to have two trauma cases matching to the same TBIMS case, if two 
weights are reasonably close, then it is better to throw out that TBIMS case, then to risk 
incorrectly choosing the true match. Of note, when applying Tier III criteria (CWD>7) in this 
study, we noticed a reduction in sensitivity with only small improvements in PPV, which 
suggests that this criterion may be too stringent, and Tier II may be sufficient for practical 
applications.   
The data quality, m, is also another important consideration when conducting a 
probabilistic match. We observed that a majority of m values were comparable (within 20% 
percent difference) between the current study and the prior study123 (data not shown).  In moving 
forward to a national merge, we plan to use the m values derived from the current study because 
of its larger sample size relative to the prior study. 
Our study has limitations that should be considered. First, our deterministic linkage was 
based on cases from a limited time period (1999-2012). Availability of validated matching 
variables in the algorithm can change over time. For example, systolic blood pressure and 
respiratory rate are no longer collected in TBIMS after 2013. Therefore, a regular reevaluation 
and adaptation of this algorithm likely will be needed at later points in time. Also, there could be 
other unmeasured or unidentified variables which may have higher data quality and lower 
random agreement rate than current matching fields in our matching algorithm. Based on a 
probabilistic algorithm developed from a single site123, the present study refined and validated 
this algorithm to match patients in the TBIMS to the NTDB in another independent single 
medical center.  Due to the availability of true match status for these patients, we could calculate 
validity metrics to assess the sensitivity and PPV of our algorithm.   
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2.5.1 Implications of the Project and Future Directions 
Our future directions are to apply this refined protocol to the multi-site TBIMS and 
NTDB using only probabilistic matching. With the advent of the Federal Interagency Traumatic 
Brain Injury Research (FITBIR) network, there is a push by the United States federal 
government to share data across the entire TBI research field. The merger of the TBIMS and 
NTDB adds to this growing movement of data linking; combining these two datasets is of 
immense interest in answering a wealth of previously unexplored research questions on the 
relationships between acute care variables and hospital course on long-term outcomes among 
individuals with TBI. The NTDB contains a wealth of data on the acute hospitalization, 
including procedure codes, complication codes, and extensive injury information (cerebral and 
extracerebral injury severity). However, a major limitation of the NTDB is that there is only 
follow-up information until hospital discharge, which restricts the scope of research questions 
that can be answered. In the TBIMS National Database, there is a wealth of follow-up 
information years after the injury, until a patient is deceased, allowing researchers to assess 
chronic recovery from moderate to severe TBI. The TBIMS National Database has only limited 
data collection for acute variables; therefore, the long-term effects of acute factors, such as 
procedures and complications, immediately after TBI cannot be assessed fully without full 
access to trauma care data. For instance, one such application of initial single site trauma-rehab 
merged dataset114 was the examination of the long-term effects of hospital-acquired pneumonia 
on global outcomes after TBI. Examining hospital-acquired pneumonia effects on long-term 
recovery for thousands of individuals with data captured in the TBIMS national dataset may have 
immense implications for the field of TBI, as there is still equivocation in clinical care guidelines 
with respect to the administration of antibiotic prophylaxis for ventilated patients with TBI. This 
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initial finding serves as an exemplar for the tremendous potential of our merged database to 
serve as a platform to address previously unanswerable research questions that have the potential 
to impact clinical care and future research priorities. It is also important to consider that our 
methods are not confined to TBI alone, and could have a lasting impact on other rehabilitation 
disciplines. That is, other model systems injury databases, specifically spinal cord injury and 
burn injury, also may be well suited for probabilistic matching with the NTDB in future studies. 
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3.0  AIM 2: EFFECTS OF HOSPITAL-ACQUIRED PNEUMONIA ON LONG-TERM 
RECOVERY AND HOSPITAL RESOURCE UTILIZATION FOLLOWING 
MODERATE-TO-SEVERE TRAUMATIC BRAIN INJURY  
3.1 ABSTRACT 
Individuals with moderate-to-severe Traumatic Brain Injury (TBI) have extended 
inpatient hospital stays, often including prolonged mechanical ventilation, which increases the 
risk for infections, such as pneumonia. Studies have shown the negative short-term effects of 
hospital-acquired pneumonia (HAP) on hospital-based outcomes; however, little is known of its 
long-term effects. The primary objective of this study was to determine the association between 
HAP and long-term disability after TBI. A secondary objective was to identify associations 
between HAP and healthcare utilization metrics. The National Trauma Databank (NTDB) and 
the Traumatic Brain Injury Model Systems (TBI-MS) were merged to derive a cohort of n=3717 
adults with TBI. Exposure data were gathered from the trauma database, and outcomes were 
gathered from the TBIMS. The primary outcome was the Glasgow Outcome Scale-Extended, 
which was collected at 1, 2 and 5 years post-injury. GOS-E was categorized as favorable (>5) or 
unfavorable (≤5) outcomes. A generalized estimating equation (GEE) model was fitted to 
estimate the effects of HAP on GOS-E over the first five years post-TBI, adjusting for age, race, 
ventilation status, brain injury severity, injury severity score (ISS), thoracic AIS ≥3, mechanism 
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of injury, intraventricular hemorrhage status, and subarachnoid hemorrhage status. Individuals 
with HAP were at a 34% (OR=1.34, 95% CI 1.15, 1.56) increased odds for unfavorable GOS-E 
over the first five years post-TBI compared to individuals without HAP, after adjustment for 
relevant demographic and clinical covariates. Individuals with HAP, compared to no HAP, spent 
10.1 days longer in acute care and 4.8 days longer in inpatient rehabilitation, and they had less 
efficient functional improvement during inpatient rehabilitation. Individuals with HAP during 
acute hospitalization have worse long-term prognosis and greater healthcare utilization post-TBI. 
Preventing HAP may be cost-effective and may improve long-term recovery for individuals with 
moderate-to-severe TBI. Future studies should compare the effectiveness of different 
prophylaxis methods to prevent HAP, including early extubation and early mobilization.  
3.2 INTRODUCTION 
An estimated 2.5 million Americans annually have an emergency department visit, are 
hospitalized with, or die due to traumatic brain injury (TBI).125 Nearly half of patients 
hospitalized with TBI experience long-term morbidity from their injuries, contributing to a large 
proportion of US citizens living with chronic disability.126 To prevent the high disability burden 
and associated costs, TBI researchers have focused on identifying acute predictors of long-term 
disability, including injury severity based on the Glasgow Coma Scale (GCS),127–129 systemic 
hypotension,130 intracranial pressure,131 and post-traumatic hydrocephalus.132,133 Other studies 
demonstrate relationships between TBI-related disability and demographic factors like older age 
at injury,134 female sex,7,135 minority race,2,136 and lower socioeconomic status.2  
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An underemphasized area of TBI research is the contribution of acute systemic infection 
to long-term recovery. Many patients with moderate-to-severe TBI require mechanical 
ventilation in the days following their injuries. A common complication of prolonged mechanical 
ventilation is hospital-acquired pneumonia (HAP), caused by pathogens entering the lower 
respiratory tract and lung parenchyma. In observational studies, HAP incidence rates range from 
30-61% in TBI populations.112–114 Variation in incidence estimates arise from heterogeneous 
cohorts, including cohorts restricted to only ventilated patients. Ventilation is an important 
predictor for incident HAP after TBI, with each additional ventilator day conferring a 7% 
increased risk for infection.109 Other variables associated with HAP incidence after TBI include 
thoracic Abbreviated Injury Scale (AIS) score ≥3 and gastric aspiration.113 Some individuals 
with TBI also experience a period of acute lymphocyte dysfunction following injury, known as 
lymphopenia.137 The result of persistent lymphopenia is suppressed immunity and a decreased 
capacity to fight pathogens, which can increase the risk for opportunistic infections, like 
pneumonia.103–107 
Incidence of HAP directly increases healthcare utilization and expenditures. Critically ill 
patients with HAP require roughly $40,000 more in acute hospitalization costs, and they also 
require approximately twice the intensive care unit and hospital lengths of stay (LOS) compared 
to critically ill patients without HAP.112,138 One study evaluating acquired brain injury patients 
determined that individuals with ventilator-associated pneumonia (VAP) had higher hospital 
costs, longer LOS, and more readmissions compared to individuals without VAP.139 
 Past TBI studies characterizing HAP have examined the short-term impact of HAP on 
cost and acute hospital outcomes.109–112 A gap exists in understanding the long-term effects of 
HAP in this population. Two recent small studies lend preliminary evidence that HAP negatively 
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impacts long-term outcomes following injury.114,140 To build upon these studies, a large multi-
site observational study with longitudinal follow-up is necessary to more accurately and 
precisely estimate the long-term effects of HAP on disability and hospital resource utilization 
after TBI. To this end, we leveraged a large probabilistically-merged database of the National 
Trauma Databank (NTDB) and TBI Model Systems (TBIMS) National Database. The study 
objectives were to: 1) determine the long-term effects of HAP on disability after moderate-to-
severe TBI; and 2) compare hospital resource utilization metrics between individuals with and 
without HAP. 
3.3 METHODS AND MATERIALS 
All TBI Model Systems centers represented in this study had approved local Institutional 
Review Board protocols. The present study used data from two large databases: the NTDB and 
the TBIMS National Database. The NTDB is the largest aggregation of trauma registry data in 
the United States. Participating hospitals contribute information on all trauma patients treated at 
their institution. Deidentified data are submitted to the NTDB and compiled for hospital 
benchmarking, data quality reports, and addressing trauma-related research questions. The 
TBIMS is a prospective cohort study funded by the National Institute on Disability Independent 
Living and Rehabilitation Research that includes data collected at 16 acute rehabilitation centers. 
Included patients received their acute care within 72 hours of injury at a designated acute care 
hospital, survived through acute care, and were stable medically to receive rehabilitation. Other 
TBIMS inclusion criteria include: a moderate-to-severe TBI (post-traumatic amnesia>24 hours, 
intracranial neuroimaging abnormalities, loss of consciousness exceeding 30 minutes, or GCS 
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less than 13) and age 16+ years at time of injury.141 Data are collected at enrollment and years 1, 
2, and 5, as well as every 5 years afterward.  
We used a probabilistic matching algorithm to combine the de-identified NTDB and 
TBIMS. The merger of the two databases was possible because participants in the TBIMS had a 
trauma record submitted to the NTDB. We developed the algorithm in two sites where exact 
matches on patient identifiers were available to form a deterministic dataset to quantitatively 
assess the veracity (e.g. sensitivity, positive predictive value) of our algorithm. We previously 
published detailed methods used for algorithm development142 and validation.143 The final 
NTDB-TBIMS cohort contained n=4022 individuals with TBI, injured between the years 1998-
2015. We further restricted our cohort to participants injured between 1998-2013 to examine 
five-year outcomes (n=3712). There were 21 NTDB trauma facilities across 17 TBIMS centers 
represented in the present dataset.  
The specific variables used in this study from the NTDB and TBIMS, along with a 
detailed description of each variable, are provided in Table 3. The exposure of interest in this 
study is HAP, and the primary outcome is the Glasgow Outcome Scale-Extended (GOS-E) 
score144, assessed at 1, 2, and 5 years post-injury. For the purposes of this analysis, scores were 
dichotomized ≤5 (unfavorable outcomes) vs. >5 (favorable outcomes), as this represents the 
distinction between severe disability and moderate disability or good recovery.144 Secondary 
descriptive analyses were conducted to examine the association between HAP and variables 
related to hospital resource utilization: acute care LOS, rehabilitation LOS, and change in 
Functional Independence Measure (FIM) scores over time (FIM efficiency). 
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Table 3. Description of measures 
NTDB measures Construct Description of Measure 
HAP Primary exposure; 
Pneumonia in 
hospital 
 Documentation for HAP was defined as one 
of two criteria,145 either:  
1. Rales or dullness on a physical 
examination of the chest and any of the 
following: new onset purulent sputum, 
organism isolated from blood culture, or 
isolation of pathogen from specimen 
obtained by transtracheal aspirate or 
biopsy; OR  
2. positive chest radiographic exam and 
any of the following: new onset purulent 
sputum, organism from the blood, 
isolation of pathogen from specimen 
isolated from transtracheal aspirate or 
biopsy, isolation of virus or detection of 
viral antigen from respiratory secretions, 
diagnostic single antibody titer (IgM) or 
4-fold increase in paired serum sample 
(IgG) for pathogen, or histopathologic 
evidence of pneumonia 
ISS Injury Severity-all 
body regions 
 An anatomic trauma severity scale derived 
from the AIS that quantifies overall injury 
severity across eight body regions146 
 Scores range from 1-6, with 1 being minor 
and 6 unsurvivable 
 ISS is the sum of squares of the 3 most 
severely injured body regions 
Non-head ISS Injury Severity-all 
non-head body 
regions 
 The Non-head ISS was calculated using AIS 
region scores 
 The sum of squares of the 3 most severe 
non-head body regions  
Thoracic AIS Thoracic injury 
severity 
 AIS thoracic region score 
 Scores range from 1-6, with 1 being minor 
and 6 unsurvivable 
 Individuals with no thoracic injuries were 
assigned a score of 0 
 Significant thoracic injury was classified as a 
thoracic AIS score ≥3 
Ventilation Status Ventilation  ICD-9 Procedure code range from 96.7-
96.72 
Ventilation days Number of days on a 
ventilator 
 Number of days on ventilator support among 
individuals on a ventilator 
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Table 3 Continued 
TBIMS measures   
Age Age  Age at injury 
Race Race  Grouped as White, Black, or Other  
Brain Injury Severity Brain Injury Severity 
based on DoD scale 
 Calculated variable consisting of two 
categories, moderate or severe injuries, 
which is a function of the Glasgow Coma 
Scale (GCS), post-traumatic amnesia (PTA), 
and number of days it takes to follow 
commands 
 Moderate injuries are defined by a GCS 
between 9-12, PTA between 0-7 days, or 
days to follow commands ≤1 day 
 Severe injuries were defined as a GCS 
between 3-8, PTA >8 days, or days to follow 
commands >1 day 
MOI Cause of injury  Grouped as Motor Vehicle, Fall, Pedestrian, 
or Other  
CT scan findings  Nature of TBI   Trained abstractors review patient electronic 
medical records to document presence or 
absence of neuropathology on computed 
tomography images 
 Grouped as presence/absence of: SDH, 
EDH, IVH, and SAH  
Payor Status Insurance  Payor was dichotomized as Medicare or 
Medicaid vs. all other payment sources 
Rehabilitation Interruption Interruption to 
Rehabilitation Care 
 Short-term interruptions during inpatient 
rehabilitation to acute care 
Acute care LOS Number of hospital 
days in acute care 
 Hospital days in acute care 
Rehabilitation LOS Number of hospital 
days in rehabilitation 
 Hospital days in rehabilitation 
FIM efficiency Rate of change in 
FIM over the course 
of Rehabilitation  
 Calculated variable from the formula: 
(FIMdischarge-FIMadmission)/(Rehab LOS) 
Rehospitalization 5- year 
Rehospitalization 
 All-cause rehospitalization at any point at 1, 
2, or 5 years post-injury 
GOS-E 
 
 
 
 
 
 
 
 
 
 
Primary outcome; 
Global disability 
measure 
 A trained research assistant conducts a 20-
question structured interview that answers a 
variety of questions pertaining to patient’s 
current condition, covering the following 
topics: 1) level of consciousness, 2) 
independence at home, 3) independence 
outside home, 4) return to work, 5) 
participation in social and leisure activities, 
6) family and friendships, and their 7) return 
to normal life.  
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Table 3 Continued  The range of scores are from 1-8, with 
higher scores corresponding to better 
recovery. 
 Scores were dichotomized ≤5 (unfavorable 
outcomes) vs. >5 (favorable outcomes) 
Abbreviations: HAP, Hospital-acquired Pneumonia; ISS, Injury Severity Scale; AIS, Abbreviated Injury Scale; 
DoD, Department of Defense; MOI, Mechanism of Injury; LOS, length of stay, GCS, Glasgow Coma Scale; Post-
traumatic Amnesia (PTA); Functional Independence Measure (FIM); GOS-E, Glasgow Outcome Scale-Extended 
Scale; CT, Computed Tomography; SDH, subdural hematoma, EDH, epidural hematoma, IVH, intraventricular 
hemorrhage; SAH, subarachnoid hemorrhage 
 
Though probabilistic matching is common in birth cohorts and life-course studies,147 its 
use in merging databases in trauma, surgery, and rehabilitation is novel. To evaluate the integrity 
of this approach for our purposes, we developed a deterministic cohort from two TBIMS sites to 
conduct a post-hoc sensitivity analysis as an internal validation measure to examine the veracity 
of our primary findings from the probabilistically-derived cohort.  This deterministic cohort 
included n=775 individuals with TBI injured between 2002-2013. 
3.3.1 Statistical analysis 
Demographic and clinical variables were compared by HAP status and GOS-E. Means 
and standard errors described continuous variables, and frequency and percentages described 
categorical variables. Chi-square tests compared categorical variables, and t-tests or Mann 
Whitney U test, were used to compare continuous variables by HAP status and GOS-E score.  
A generalized estimating equation (GEE) model was used for the primary analysis 
assessing the relationship between HAP and 1, 2 and 5-year GOS-E. Models were fit using an 
unstructured correlation structure. Covariates included: age, race, ventilation status, brain injury 
severity, injury severity score (ISS), thoracic AIS ≥3, mechanism of injury, intraventricular 
hemorrhage status, and subarachnoid hemorrhage status. To observe the effects of the covariates 
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on the effect of HAP on GOS-E, a series of four models are presented: Model 1 (unadjusted), 
Model 2 (adjusts for age effects), Model 3 (adjusts for age and race only), and Model 4 (fully 
adjusted for all chosen demographic and clinical variables). We chose covariates that were 
associated with HAP and 1-year GOS-E at an α=0.20 level. Chosen covariates were not in the 
pathway between HAP and GOS-E. The same covariates were included in the primary, 
secondary, and sensitivity analyses.   
In order to determine the effects of HAP on hospital resource utilization, analysis of 
covariance (ANCOVA) models were used to compute covariate-adjusted mean scores for acute 
LOS, rehab LOS, and FIM efficiency by HAP status. FIM efficiency is the change in FIM score 
during rehabilitation divided by the rehabilitation LOS. SAS 9.4 was used for all statistical 
analysis (Cary, NC).148 
3.4 RESULTS 
3.4.1 Demographic and Clinical Variables by HAP Status 
The cohort included n=1212 (32.7%) individuals with HAP and n=2500 (67.3%) 
individuals without HAP. The demographic and clinical variables by HAP status are presented in 
Table 4. Individuals with HAP were more likely to be younger and male than individuals 
without HAP (p<0.001 both comparisons). Injury Severity Scale (ISS) score and non-head ISS 
were significantly higher among individuals with HAP versus no HAP (p<0.001 both 
comparisons). A greater proportion of individuals with HAP had a thoracic AIS score ≥3, were 
more frequently on a ventilator, spent more days on a ventilator, and had longer acute and 
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rehabilitation LOS compared to individuals without HAP (p<0.001 all comparisons). A greater 
proportion of individuals with HAP had a rehabilitation interruption compared to no HAP 
(p=0.027). A greater proportion of individuals with HAP had an intraventricular hemorrhage 
(IVH) and subarachnoid hemorrhage (SAH) compared to no HAP (p<0.01 both comparisons). 
The mechanism of injury also varied by HAP status (p<0.001), with a greater proportion of 
patients with HAP suffering MVA.  
Table 4. NTDB Demographics and Clinical Variables by HAP Status 
Variable HAP (n=1212) No HAP (n=2500) p-value 
Age (mean, SE) 38.36 (0.48) 43.45 (0.41) <0.001* 
Sex (men, %¥) 970 (80.03) 1756 (70.27) <0.001* 
Race (n, %¥) 
   White 
   Black 
   Other 
 
851 (70.21) 
209 (17.24) 
152 (12.54) 
 
1678 (67.15) 
473 (18.93) 
348 (13.93) 
0.170 
Brain Injury Severity (n, %) 
   Moderate 
   Severe 
 
77 (6.49) 
1110 (93.51) 
 
696 (28.22) 
1770 (71.78) 
<0.001* 
ISS (mean, SE) 28.18 (0.36) 23.22 (0.23) <0.001* 
ISS Non-Head (mean, SE) 11.28 (0.31) 8.49 (0.20) <0.001* 
Thoracic AIS ≥3 (n,%) 477 (44.3) 603 (26.93) <0.001* 
Ventilation status (n, %¥) 795 (65.59) 972 (38.88) <0.001* 
Ventilation days (mean, SE) 10.32 (0.33) 3.21 (0.15) <0.001* 
Cranial surgery status (n, %¥) 279 (27.30) 551 (25.94) 0.418 
Payor status (n, %¥) 
   Government assistance  
   Private pay 
 
420 (37.80) 
691 (62.20) 
 
896 (38.96) 
1404 (61.04) 
0.517 
Acute care length of stay (mean, SE) 30.27 (0.49) 16.96 (0.27) <0.001* 
Rehabilitation length of stay (mean, SE) 30.44 (0.72) 23.68 (0.47) <0.001* 
Rehabilitation Interruptions (n, %¥) 77 (6.63) 115 (4.84) 0.027* 
CT Injury Type (n, %¥) 
   SDH 
   EDH 
   IVH 
   SAH 
 
663 (55.02) 
139 (11.54) 
405 (33.61) 
860 (71.37) 
 
1296 (52.26) 
311 (12.54) 
651 (26.25) 
1661 (66.98) 
 
0.115 
0.382 
<0.001* 
0.007* 
Mechanism of Injury (n, %¥) 
   MVA 
   Assault/Violence 
   Fall 
   Pedestrian 
   Other 
 
802 (66.23) 
90 (7.43) 
211 (17.42) 
80 (6.61) 
28 (2.31) 
 
1240 (49.98) 
270 (10.88) 
697 (28.09) 
172 (6.93) 
102 (4.11) 
<0.001* 
Abbreviations: GCS, Glasgow Coma Scale; ISS, Injury Severity Score; SDH, Subdural hematoma; EDH, Epidural 
hematoma; IVH, intraventricular hemorrhage; SAH, subarachnoid hemorrhage 
44 
3.4.2 Demographic and Clinical Variables by GOS-E at 1 year 
Demographic and clinical variables by unfavorable/favorable 1-year GOS-E status are 
presented in Table 5. There were n=1491 (47.5%) individuals with unfavorable GOS-E scores 
and n=1651 (52.5%) individuals with favorable GOS-E scores. There were significant 
differences in GOS-E by race (p<0.001) and payor status (p<0.001). Mechanism of injury was 
significantly different by GOS-E status (p<0.001). Individuals with unfavorable GOS-E scores 
were older, more often on a ventilator, had more ventilator days, longer acute care and 
rehabilitation LOS, and a greater proportion of rehabilitation interruptions compared to 
individuals with favorable GOS-E scores (p<0.001 all comparisons). Individuals with 
unfavorable outcomes more often experienced SDH, IVH, and SAH injuries (p<0.01 all 
comparisons).  
Table 5. NTDB Demographic and Clinical Variables by GOS-E Status at 1 Year 
Variable Unfavorable GOS-E  
(n=1491) 
Favorable GOS-E  
(n=1651) 
p-value 
Age (mean, SE) 44.10 (0.50) 39.74 (0.48) <0.001* 
Sex (men, %¥) 1099 (73.71) 1213 (73.47) 0.880 
Race (n, %¥) 
   White 
   Black 
   Other 
 
953 (63.92) 
344 (23.07) 
194 (13.01) 
 
1232 (74.62) 
221 (13.39) 
198 (11.99) 
<0.001* 
Brain Injury Severity (n, %) 
   Moderate 
   Severe 
 
245 (16.91) 
1204 (83.09) 
 
392 (23.80) 
1255 (76.20) 
<0.001* 
ISS (mean, SE) 25.37 (0.32) 24.75 (0.29) 0.182 
ISS Non-Head (mean, SE) 9.51 (0.27) 9.62 (0.26) 0.675 
Thoracic AIS ≥3 (n,%) 422 (31.24) 498 (33.56) 0.187 
Ventilation status (n, %¥) 773 (51.84) 744 (45.06) <0.001* 
Ventilation days (mean, SE) 7.04 (0.27) 4.30 (0.21) <0.001* 
Cranial surgery status (n, %¥) 411 (32.01) 334 (22.58) <0.001* 
Payor status (n, %¥) 
   Government assistance  
   Private pay 
 
662 (48.53) 
702 (51.47) 
 
437 (28.41) 
1101 (71.59) 
<0.001* 
Acute care length of stay (mean, SE) 25.76 (0.46) 17.48 (0.30) <0.001* 
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Table 5 Continued 
Rehabilitation length of stay (mean, 
SE) 
32.12 (0.77) 20.40 (0.37) <0.001* 
Rehabilitation Interruptions (n, %¥) 117 (8.36) 48 (3.02) <0.001* 
CT Injury Type (n, %¥) 
   SDH 
   EDH 
   IVH 
   SAH 
 
858 (58.13) 
180 (12.20) 
504 (34.15) 
1057 (71.61) 
 
834 (50.73) 
208 (12.65) 
434 (26.40) 
1104 (67.15) 
 
<0.001* 
0.699 
<0.001* 
0.007* 
 
Mechanism of Injury (n, %¥) 
   MVA 
   Assault/Violence 
   Fall 
   Pedestrian 
   Other 
 
790 (53.27) 
176 (6.76) 
389 (26.23) 
94 (5.72) 
87 (5.30) 
 
953 (58.00) 
111 (6.76) 
398 (24.22) 
94 (5.72) 
87 (5.30) 
<0.001* 
 
Abbreviations: GCS, Glasgow Coma Scale; ISS, Injury Severity Score; CT, Computed Tomography; SDH, 
Subdural hematoma; EDH, Epidural hematoma; IVH, intraventricular hemorrhage; SAH, subarachnoid hemorrhage 
3.4.3 Primary analysis: GEE Model of GOS-E at 1, 2, and 5 years after TBI using NTDB 
probabilistic cohort 
The GEE models for the GOS-E primary analysis are provided in Table 6. In the 
unadjusted model, individuals with HAP had a 28% increased odds for unfavorable GOS-E 
scores compared to individuals without HAP (OR=1.28, 95% CI (1.14, 1.45), p<0.001). After 
adjustment for age only, individuals with HAP had a 48% increased odds for unfavorable GOS-E 
scores compared to individuals without HAP (OR=1.48, 95% CI (1.29, 1.69), p<0.001). After 
adding race, individuals with HAP had a 51% increased odds for unfavorable GOS-E scores 
compared to individuals without HAP (OR=1.51, 95% CI (1.32, 1.73), p<0.001). In the fully 
adjusted model, individuals with HAP had a 34% increased odds for unfavorable GOS-E scores 
compared to individuals without HAP (OR=1.34, 95% CI (1.15, 1.56), p<0.001). 
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Table 6. Probabilistic Cohort GEE Regression Model for Repeated Measures GOS-E at 1, 2, and 5 years 
  Model 1£ Model 2§  Model 3¥ Model 4€  
  Odds ratio  
(95% CI) 
p-value Odds ratio  
(95% CI) 
p-value Odds ratio  
(95% CI) 
p-value Odds ratio  
(95% CI) 
p-value 
HAP 
   No (reference) 
   Yes 
 
 
(reference) 
1.28 (1.14, 1.45) 
<0.001* 
 
 
 
(reference) 
1.48 (1.29, 1.69) 
<0.001*  
 
(reference) 
1.51 (1.32, 1.73) 
<0.001*  
 
(reference) 
1.34 (1.15, 1.56) 
<0.001* 
*: statistically significant at p<0.05 
£: Model 1: Unadjusted  
§: Model 2: Adjusted for Age only 
¥: Model 3: Adjusted for Demographic Variables: Age and Race 
€: Model 4: Adjusted Demographic and Clinical Variables: Age, Race, ventilation status, brain injury 
severity, ISS, Thoracic AIS ≥3, mechanism of injury, intraventricular hemorrhage status, subarachnoid 
hemorrhage status 
 
3.4.4 Sensitivity analysis: GEE Model of GOS-E at 1, 2, and 5 years after TBI using 
Deterministic Cohort 
Using only the deterministic cohort, the unadjusted analysis showed individuals with 
HAP were at a 44% increased odds for unfavorable GOS-E scores compared to individuals 
without HAP (OR=1.44, 95% CI (1.05, 1.98), p=0.022) (Table 7). After adjusting for only age, 
individuals with HAP had a 69% increased odds for unfavorable GOS-E compared to individuals 
without HAP (OR=1.69, 95% CI (1.22, 1.34), p=0.002). After adding race, individuals with HAP 
had a 72% increased odds for unfavorable GOS-E compared to no HAP (OR=1.72, 95% CI 
(1.23, 2.39), p=0.001). In the full adjusted model, individuals with HAP had a 63% increased 
odds for unfavorable GOS-E compared with individuals without HAP (OR=1.63, 95% CI (1.16, 
2.30), p=0.005).   
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Table 7. Deterministic Cohort GEE Regression Model for Repeated Measures GOS-E at 1, 2, and 5 years 
  Model 1£ Model 2§  Model 3¥ Model 4€  
  Odds ratio  
(95% CI) 
p-value Odds ratio  
(95% CI) 
p-value Odds ratio  
(95% CI) 
p-value Odds ratio  
(95% CI) 
p-value 
HAP 
   No (reference) 
   Yes 
 
 
(reference) 
1.44 (1.05, 1.98) 
0.022* 
 
 
 
(reference) 
1.69 (1.22, 1.34) 
0.002*  
 
(reference) 
1.72 (1.23, 2.39) 
0.001*  
 
(reference) 
1.63 (1.16, 2.30) 
0.005* 
*: statistically significant at p<0.05 
£: Model 1: Unadjusted  
§: Model 2: Adjusted for Age only 
¥: Model 3: Adjusted for Demographic Variables: Age and Race 
€: Model 4: Adjusted Demographic and Clinical Variables: Age, Race, ventilation status, brain injury 
severity, ISS, Thoracic AIS ≥3, mechanism of injury, intraventricular hemorrhage status, subarachnoid 
hemorrhage status 
3.4.5 Secondary analysis: Hospital utilization variables by HAP Status 
After covariate adjustment, individuals with HAP, compared to no HAP, had on average 
10.1 more days in acute care LOS and 4.8 more days in rehabilitation LOS (p<0.001 both 
comparisons). The unadjusted FIM efficiency for individuals with HAP was 2.02 compared to 
2.31 for individuals without HAP. After adjustment for covariates, individuals with HAP had 
0.29 reduced FIM efficiency during rehabilitation compared to no HAP (p<0.001).  
3.5 DISCUSSION 
Our findings highlight HAP as a meaningful early modifiable risk factor that impacts TBI 
recovery and hospital resource utilization. We observed a HAP incidence rate of 32.7%, which is 
similar to past estimates.114 The present study provides evidence that the effects of acute HAP 
extend beyond the infection period itself and may persist for years after injury, perhaps through 
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the propagation of chronic inflammatory milieu86 and decreased or delayed rehabilitation 
participation. In addition to poorer long-term prognosis, individuals with HAP also had longer 
average hospital stays and tended to have decreased efficiency in attaining functional 
rehabilitation gains compared to their counterparts without HAP. Focused and concerted efforts 
should be made to prevent HAP in this susceptible population. 
In this study, we examined the effects of HAP on long-term outcomes among patients 
with TBI who survived initial injury and received inpatient rehabilitation. Recent work by 
Esnault and colleagues113 examined the effects of early-onset VAP among 175 individuals with 
severe TBI and observed an elevated odds (OR=2.71, 95% CI: 1.01-7.25) for more unfavorable 
GOS scores at 1-year. Similarly, a small pilot study (n=141) led by our research group114 used a 
similar design as the present study. To avoid any duplicity in reporting, no individuals in our 
prior study were included in our present analysis. We previously showed HAP carried a 4.6 
times (95% CI: 1.80-11.60) increased odds for unfavorable outcomes in a longitudinal model.114 
The small sample size and single-site design by Esnault et al.113 and Kesinger et al.114 likely 
account for the inflated effect sizes and wide confidence intervals compared to the present larger 
study where we observed a 34% increased odds of unfavorable GOS-E from HAP in the fully 
adjusted model.  
In another previous descriptive epidemiological study, Zygun and colleagues112 showed 
an incidence rate of VAP of 45% among 134 individuals with severe TBI, which the authors 
report is nearly three times the rate reported for all general trauma patients, according to the 
National Nosocomial Infections Surveillance program report.149 This observation provides 
evidence that individuals with severe TBI are particularly vulnerable to hospital infections. Some 
individuals with TBI experience a period of lymphopenia beginning early after injury.137 
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Persistent lymphopenia reflects suppressed adaptive immunity and a decreased capacity to fight 
pathogen exposure. Lymphopenia has been documented in trauma populations,103–107 in addition 
to preliminary observations of lymphopenia in TBI.137 Clinical and injury factors, such as 
prolonged mechanical ventilation and concurrent thoracic injuries, are also risk factors for HAP. 
More severely injured patients are at a greater risk for developing HAP and poorer outcomes; 
however, our results show the harmful effects of HAP are independent of injury severity. 
In our present cohort, we observed a modest negative confounding of the effect of HAP 
on outcome driven by age. We observed younger age is associated with a greater incidence of 
HAP, but is protective against unfavorable outcomes after TBI. Though this association may 
seem counterintuitive, it has been previously documented in the TBIMS National Database6 and 
makes sense given the mechanism of injuries experienced by older vs. younger individuals. 
Older individuals more often sustain less severe isolated brain injuries from falls; whereas, 
younger individuals are more likely to suffer more severe injuries and polytrauma. These 
findings highlight that HAP prevention efforts should be directed across the age span, 
particularly among younger ages, as HAP is both more common at younger ages and a large 
proportion of individuals with unfavorable outcomes had HAP. 
Incidence of HAP after TBI also has significant implications for hospital resource 
utilization. Our results showed that individuals with HAP had longer acute and rehabilitation 
lengths of stay compared to individuals without HAP. We also determined that individuals with 
HAP were more likely to have rehabilitation interruption and had decreased FIM efficiency by 
0.29. In other words, patients with HAP required roughly 30% additional days in rehabilitation to 
achieve similar functional gains as patients without HAP. Preventing HAP in TBI populations 
may yield substantial cost-related benefits.108  
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This study highlights the importance of infection prophylaxis in TBI populations; HAP is 
both extremely common and often preventable. Given the high morbidity and mortality 
associated with TBI across the lifespan, the importance of modifiable factors that can result in 
improved outcomes cannot be underemphasized. The recent 2016 4th edition Guidelines for the 
Management of Severe Traumatic Brain Injury16 recommends Level IIA evidence for early 
tracheostomy as a method for infection prophylaxis. Others have also suggested early extubation 
is important.150 A potentially cost-effective intervention is early mobility protocols during acute 
care, for those who are able, which has been shown to be efficacious in reducing incidence of 
HAP in neurointensive care unit patients.151 Another study in an acute stroke population found 
that early screening and treatment of dysphagia was associated with a decreased rate of HAP.152 
A systematic review of 28 trials of intensive care and nursing home patients also found 
chlorhexidine oral disinfectants were effective for HAP prophylaxis.153 Future studies in TBI 
would benefit from conducting trials for HAP prevention.  
There are limitations of this work that warrant consideration. We assessed HAP instead 
of VAP because there was no clear information on time until infection in the NTDB. Despite 
this, our results indicate that the deleterious effects of HAP exist independent of ventilation 
status. Furthermore, NTDB complication codes are subject to underreporting,154 which could 
result in an underestimation of HAP incidence and bias the effect towards the null. It is a 
reasonable assumption that misclassification of HAP in the NTDB is non-differential to the 
outcome, as the outcome was gathered from the TBIMS National Database. The primary analysis 
was conducted using a probabilistically-matched cohort; therefore, it is possible that a small 
percentage of the pairs were incorrectly matched. However, based on our previous algorithm 
development142 and validation143 studies, we have empirical evidence to suggest that mismatched 
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pairs were likely very rare (<2%). Also, the converging results in our sensitivity analysis from a 
deterministic dataset support the observation of the harmful effects of HAP on outcomes after 
TBI found in the primary analysis. In our secondary analysis, the data we present is a proxy for 
hospital resource utilization; however, we do not have available claims or cost data that may be a 
truer measure of utilization.  
We demonstrate that HAP increases odds for unfavorable outcomes by 34% up to five 
years after TBI. This study provides a meaningful contribution to the field by highlighting the 
deleterious long-term effects of acute care HAP in a large sample of individuals with TBI. The 
work supports the need for future studies to expand research on infection prophylaxis during 
acute hospitalization. TBI populations are particularly vulnerable to incident HAP, and concerted 
efforts are needed to prevent primary infections to improve long-term recovery. 
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4.0  AIM 3: RELATIONSHIP BETWEEN ACUTE SERUM ESTRADIOL AND 
TUMOR NECROSIS FACTOR-ALPHA AND RISK FOR MORTALITY AFTER 
SEVERE TRAUMATIC BRAIN INJURY 
4.1 ABSTRACT 
Individuals with severe Traumatic Brain Injury (TBI) are at risk for systemic compromise 
and acute mortality. Tumor necrosis factor-alpha (TNFα) is a major mediator of systemic shock 
and is an extra-gonadal transcription factor for estradiol (E2) production, a documented 
prognostic marker of mortality in TBI populations. Our study objectives are to test the 
hypotheses: 1) of a positive feedback relationship over time between acute serum TNFα and E2; 
and 2) acute concentrations of E2 and TNFα are prognostic indicators of mortality after severe 
TBI. This prospective cohort study included N=157 adults with severe TBI. Serum samples were 
collected from participants for the first five days post-injury. TNFα and E2 levels were averaged 
into two time epochs: first 72 hours (T1) and second 72 hours post-injury (T2). A cross-lag panel 
analysis conducted between T1 and T2 TNFα and E2 levels showed significant cross-lag effects: 
T1 TNFα was related to T2 E2, and T1 E2 was related to T2 TNFα, independent of confounders 
and autoregressive effects. Cox proportional hazards regression models determined that increases 
in T1 E2 (HR=1.82, 95% CI: 1.14, 2.89), but not T2 E2 (HR=0.91, 95% CI: 0.56, 1.47), were 
associated with increased risk for mortality. Increases in T2 TNFα (HR=2.55, 95% CI: 1.40, 
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4.64), and T1 TNFα (HR=1.46, 95% CI: 0.99, 2.17) to a lesser degree, were associated with 
increased mortality risk. E2 and TNFα are two systemic biomarkers that are interrelated and may 
be indicative of systemic compromise and increased mortality risk after severe TBI.    
4.2 INTRODUCTION 
Severe Traumatic Brain Injury (TBI) constitutes a major public health and economic 
burden in the world. Individuals with severe TBI have an increased risk for premature 
mortality155–157 and survivors often live with chronic injury-related disabilities.126 The financial 
burden of TBI in the United States is estimated at over $60 billion per year.158 There have been 
tremendous efforts over the last several decades to identify acute treatments for TBI populations. 
Despite some progress in clinical care, mortality rates for severe TBI are largely unchanged over 
the last decade.159,160 There are also still no treatments that received a Level I recommendation 
for efficacy in the recent 4th edition TBI Guidelines,16 and no treatments have been approved by 
the Food and Drug Administration following Phase III trials.  
Several large clinical trials in TBI populations have examined the efficacy of 
pharmacological dosing of agents including corticosteroids and progesterone, which target 
inflammation161,162 and hormone physiology,163,164 respectively. However, these trials161–164 
largely were ineffective or were halted prematurely because of observed harm in the treatment 
arm. Unsuccessful findings from clinical trials come despite pre-clinical TBI studies that have 
shown the efficacy of exogenous progesterone165,166 and anti-inflammatory therapies as 
neuroprotective agents.167–169 Data from observational cohort studies, however, have revealed the 
deleterious effects of excessive peripheral hormones96 and acute inflammation.74,75,170 
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Interestingly, observational studies have suggested that immune and endocrine networks are 
highly interconnected in the brain, and the regulatory connection between the two systems is 
associated with recovery following severe TBI.65 Though less is understood about endocrine-
immune cross-talk in the context of the systemic response to TBI and its associated trauma 
complex. The failure of prior TBI clinical trials now invites further study within an intriguing 
line of research regarding hormone and inflammatory physiology after TBI; studies are 
warranted to understand the inter-connectedness between peripheral immune and endocrine 
networks. 
Tumor necrosis factor-alpha (TNFα) and Estradiol (E2) are inflammatory and endocrine 
markers, respectively, that are elevated acutely in serum after severe TBI171–173 and associated 
with morbidity78 and mortality.96,174 These markers are important in the context of post-TBI 
homeostatic disturbance. After TBI, the hypothalamic-pituitary-gonadotrophic (HPG) axis is 
often dysfunctional, which leads to abnormal sex hormone products, including E2. The 
autonomic nervous system (ANS) is triggered in the trauma response, which drives the 
sympathetic nervous system (SNS) to initiate an acute phase response that leads to peripheral 
TNFα production.175–177 TNFα is the body’s major mediator of septic shock and secondary 
systemic inflammatory response syndrome.178 In the context of injury or critical illness, regulated 
release of TNFα is physiologically normal for healing; however, uncontrolled TNFα production 
may mediate a progression of systemic shock, organ dysfunction and death.90  
Observed elevations in TNFα and E2 in the setting of TBI are likely not independent. E2 
is produced by the conversion of androgens via the aromatase gene,179 and TNFα serves as a 
tissue-specific transcription factor for E2 synthesis in adipose tissue.93,118–120,180,181 Increasing E2 
production acutely has a positive feedback that contributes to exaggerated levels of inflammation 
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through reuptake inhibition of norepinephrine in lymphoid tissues.87,121 This theoretical positive-
feedback relationship is suggestive that excessive E2 in the periphery are both a cause and 
byproduct of excessive peripheral TNFα; though, this hypothesis has not been tested. 
 A positive feedback loop between the TNFα and E2 could account in some part for the 
observed increased risk for mortality seen among individuals with elevations in concentrations of 
these markers. The concept of immune-endocrine associations of these two peripheral markers 
has not been empirically tested in clinical TBI studies to date. The primary objective of the 
present study is to test the hypothesis of a positive feedback relationship between serum TNFα 
and E2 over time in the acute period following severe TBI using a cross-lag panel model. The 
secondary objective tests the prognostic effects of acute serum TNFα and E2 levels on mortality 
risk in the first six months after severe TBI. Understanding the evolving relationships between 
acute serum TNFα and E2 will provide evidence of connections between inflammatory and 
endocrine markers that are relevant to survival after severe TBI. Identifying the prognostic 
capacity of these biomarkers for mortality risk has important implications to identify at-risk 
persons with TBI. 
4.3 METHODS AND MATERIALS 
This study was approved by the Institutional Review Board for the University of 
Pittsburgh. The present report is a prospective observational cohort study that includes n=157 
adults with severe TBI. Eligible participants were between 16-70 years old, had an initial 
Glasgow Coma Scale (GCS) score of 8 or less, and had pathology present on a computed 
tomography (CT) scan. Patients with TBI were excluded if they had a history of cancer or 
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untreated thyroid disease. Next of kin were approached for consent in instances where the patient 
was unable to self-consent. Patients with TBI received care aligned with the TBI Guidelines for 
the Management of Severe Head Injury,16 which included placement of an extra-ventricular 
device for intracranial pressure monitoring, central venous catheter, arterial catheter, and 
neurosurgical intervention for the decompression of mass lesions.  
4.3.1 Serum Sample Processing 
Eligible and consented participants received a blood draw daily for the first six days 
following injury. Blood draws were obtained at 7:00 AM on most mornings, unless there was a 
direct conflict with clinical care. In instances where it was not possible to gather a morning blood 
draw, a sample was gathered at 7:00 PM. For some participants, it was not possible to receive a 
blood sample each day. After collection of the serum, samples were centrifuged and aliquoted, 
and stored at -80oC until the assaying. The serum samples were assayed for E2 using 
radioimmunoassay with Coat-A-Count® In-vitro Diagnostic Test Kit. E2 was measured using a 
125I radioimmunoassay using 100µL sample aliquots. Serum sample measurements for TNFα 
were completed using a LuminexTM bead array assay (Millipore, Billerica, Massachusetts; 
catalog number was HSCYTO-60SK). The minimum detectable limit for TNFα was 0.05 pg/mL. 
TNFα were scaled utilizing concentration standards and quality controls prior to the analysis due 
to observed variability across plates. The inter-assay and intra-assay coefficients of variation 
(CV) was <10% for both the hormone and inflammatory assays.  
57 
4.3.2 E2 and TNFα Classification: Early and Delayed Response 
E2 and TNFα were grouped into two epochs: time 1 (T1) and time 2 (T2). T1 consisted 
of data averaged over the first 72-hours after injury, and T2 consisted of data averaged over the 
second 72-hours after injury. Because individuals had missing values at various time points in 
the first week due to conflicts with regular clinical care it was not possible to do analysis by daily 
levels. 
4.3.3 Aromatase genetics: rs2470152 
DNA was extracted from participants’ whole-blood samples before transfusion. Blood 
samples were drawn into ethylenediamine tetra acetic acid vacutainer tubes, and immediately 
centrifuged to retrieve the buffy coat. The DNA was extracted using a salting out procedure.182 
The single nucleotide polymorphism (SNP) rs2470152 was genotyped as part of a larger 
genomic analysis of the aromatase gene (CYP19A1) that included four functional SNPs and 18 
tagging SNPs. A primary article examining the effects of aromatase genetics on TBI outcomes 
was previously published, and determined significant association between genetics and levels 
and global TBI outcomes.183  
4.3.4 Clinical and Demographic Variables 
Clinical and demographic variables collected in this study included: age, sex, race, best in 
24-hour Glasgow Coma Scale (GCS) score, injury severity scale (ISS) score, non-head ISS 
score, mechanism of injury, and injury type on a computed tomography (CT) scan. The GCS is a 
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physiological measure of TBI injury severity, made up of the following three components: motor 
responsiveness, verbal performance, and eye opening.127 The scores range from 3-15, with lower 
scores corresponding to more severe injuries. The best GCS score in the first 24 hours was 
utilized for analysis purposes to adjust in part for issues with an initial GCS value being 
confounded by paralytics and sedatives. The ISS is an anatomical trauma scoring scale that is a 
function of the three most severely injured body systems from the Abbreviated Injury Scale 
(AIS).184 A non-head ISS was re-calculated after removing the head body region. Presence of 
abdominal and thoracic injuries were derived from AIS region scores ≥1 for the respective 
regions. Presence of splenic injury was derived using International Classification of Disease 
Injury codes version 9 (ICD-9) code “865.” CT injury types included the subdural hematoma 
(SDH), subarachnoid hemorrhage (SAH), intraventricular hemorrhage (IVH), epidural 
hematoma (EDH), diffuse axonal injury (DAI), contusion, or other.  
4.3.5 Primary Outcome: Mortality 
 The primary outcome for this study was time until death. When applicable, this data was 
extracted from the Social Security Death Index (SSDI). The date of incident TBI was subtracted 
from the death date to calculate the time until death in days. The data was right censored at 6 
months post-injury. 
4.3.6 Statistical Analysis 
Demographic and clinical variables were examined by E2 and TNFα at T1 and T2, 
divided at the median, as well as by 6-month mortality status. Categorical variables were 
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examined using a chi-square test, and continuous variables were examined using a two-sample t-
test or a Mann Whitney-U test, where appropriate. Biomarkers were treated continuously for the 
primary analysis but were divided at the median only for the purposes of grouped comparisons 
by demographic and clinical variables. Distributions were monitored for E2 and TNFα, and 
natural log transformations were made, if deemed appropriate.  
The primary objective of this study is to assess evidence of a cross-lag effect between 
TNFα and E2. The purpose of a cross-lagged panel analysis is to determine the relationship 
between n repeatedly measured variables over time.185 The cross-lagged panel model in this 
study assessed the inter-relationships between E2 and TNFα at T1 and T2 in the first week after 
TBI. The cross-lagged panel models for E2 and TNFα at T2 can be described using two 
equations: 
E22 = β1*E21 + β2*TNFα1 + βnCn 
TNFα2 = β3*TNFα1 + β4*E21 + βnCn 
In these models, the subscripts 1 and 2 represent two time intervals, and C represents a 
matrix of relevant confounders. The corresponding beta coefficients (β1 –β4) represent the 
different paths in the cross-lag panel, as shown conceptually in Figure 7.  
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Figure 7. Conceptual Cross-Lab Panel 
In this panel, β1 and β3 represent the effect of a variable on itself at a later time epoch, 
known as autoregressive effects. The autoregressive effects represent the stability of individual 
differences in a variable over time.186 The coefficients β2 and β4 represent the cross-lag effects, or 
the relationship between a single variable at one time epoch on another variable at a later time.186 
Crucially, cross-lag effects are estimated adjusting for the prior level of the variable itself. That 
is, the association between TNFα at T1 on E2 at T2, is independent of the effects of E2 at T1. 
The cross-lag also adjusts for the residual covariance of E2 and TNFα at the same cross-sectional 
time point.  
Our secondary objective was to determine the association between T1 and T2 E2 and 
TNFα on mortality risk in the first six months post-TBI. Time until death was right censored at 
six months post-TBI. Cox proportional hazards regression models were fitted for T1 and T2 
biomarkers. Variables associated at a p<0.20 threshold with E2 or TNF, and 6-month mortality 
were included as covariates in the cross-lag panel and Cox Proportional Hazards Regression 
Model. The list of covariates included: age, GCS, contusion, DAI, SDH, and rs2470152. To 
observe the effects of the covariates on the effect size of E2 and TNFα, a series of four models 
are presented: Model 1 (unadjusted), Model 2 (adjusts for age only), Model 3 (adjusts for age, 
GCS, CT abnormalities: contusion, SDH, and DAI), and Model 4 (adjusts for age, GCS, CT 
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abnormalities: contusion, SDH, and DAI, and rs2470152). A sex interaction with E2 at T1 and 
T2 was also forced in the full adjusted model in order to test whether there are differences in the 
relationship between E2 and mortality by sex. The Harrell’s Concordance Statistic, a measure for 
model fit for Cox Regression,187 was reported for all models. Statistical analyses were performed 
using Stata 15188 and SAS 9.4.148 
4.4 RESULTS 
4.4.1 Demographic and Clinical Variables by E2 and TNFα 
Clinical and demographic variables were compared by T1 and T2 E2 (Table 8) and T1 
and T2 TNFα (Table 9) divided at the median. Median E2 at T1 was 60.0 pg/mL and 35.6 
pg/mL at T2. Median TNFα at T1 was 7.7 pg/mL and 8.5 pg/mL at T2. Older age was 
significantly associated with a higher T2 E2 (p=0.023). Individuals with higher TNFα at T1 
tended to have greater ISS (p=0.069) and non-head ISS scores (p=0.006). Individuals with 
thoracic injuries had significantly higher E2 at both time points (p<0.05). Individuals with 
splenic injuries tended to have higher E2 at T1 (p=0.060), and individuals with abdominal 
injuries had significant higher TNFα at T1 (p=0.035). Participants with a contusion were more 
likely to have higher E2 at both time points (p<0.05). Finally, rs2470152 was associated with 
higher E2 at T1 (p=0.028) and T2 (p=0.053). Specially, participants with a TC genotype were 
more often in the high E2 category, compared to TT or CC homozygotes. 
 
 
62 
Table 8. Demographic and Clinical Variables by T1 and T2 E2 
 T1  T2  
Variables E2 Above Median 
(n=75) 
E2 Below Median 
(n=74) 
p-value E2 Above Median 
(n=61) 
E2 Below Median 
(n=62) 
p-value 
Age (Mean, SE) 41.71 (2.06) 36.40 (1.69) 0.119 41.54 (2.16) 34.95 (1.99) 0.023* 
Sex (men, %) 57 (79.17) 58 (81.69) 0.704 47 (77.05) 50 (80.65) 0.625 
Race, (n, %) 
   White 
   Black  
 
68 (93.15) 
5 (6.85) 
 
69 (93.24) 
5 (6.76) 
0.982  
58 (95.08) 
3 (4.92) 
 
55 (90.16) 
6 (9.84) 
0.299 
Best in 24 hour GCS (Median, IQR) 7 (6-7) 7 (6-8) 0.105 7 (5-8) 7 (6-8) 0.438 
ISS (Mean, SE) 34.81 (1.23) 32.55 (1.18) 0.255 35.39 (1.31) 33.02 (1.35) 0.184 
Non-head ISS (Mean, SE) 13.98 (1.35) 12.29 (1.29) 0.266 14.62 (1.45) 11.73 (1.30) 0.134 
Length of Hospital Stay (Mean, SE) 18.79 (1.53) 21.77 (1.48) 0.106 19.62 (1.57) 24.42 (1.72) 0.069 
Mechanism of Injury, (n, %) 
   MVA 
   Motorcycle 
   Fall 
   Other 
 
 
32 (46.38) 
15 (21.74) 
15 (21.74) 
7 (10.14) 
 
 
37 (50.00) 
14 (18.92) 
13 (17.57) 
10 (13.51) 
0.827  
 
26 (44.07) 
16 (27.12) 
11 (18.64) 
6 (10.17) 
 
 
31 (52.54) 
9 (15.25) 
11 (18.64) 
8 (13.56) 
0.443 
CT injury type, (n, %) 
   SDH 
   SAH 
   IVH 
   EDH 
   DAI 
   Contusion 
 
48 (64.86) 
54 (72.97) 
17 (22.97) 
11 (14.86) 
17 (22.97) 
35 (47.30) 
 
 
49 (66.22) 
46 (62.16) 
24 (32.43) 
8 (10.81) 
26 (35.14) 
23 (31.08) 
 
0.863 
0.160 
0.199 
0.461 
0.103 
0.043* 
 
39 (62.90) 
48 (78.69) 
15 (24.59) 
8 (13.11) 
15 (24.59) 
32 (52.46) 
 
38 (62.30) 
39 (62.90) 
21 (33.87) 
7 (11.29) 
23 (37.10) 
20 (32.26) 
 
 
0.944 
0.054 
0.258 
0.757 
0.133 
0.023* 
Splenic injury, (n, %) 11 (14.67) 4 (5.41) 0.060 9 (14.75) 5 (8.06) 0.243 
Abdominal injury, (n, %) 22 (34.92) 28 (40.00) 0.546 23 (41.82) 20 (35.71) 0.509 
Thoracic injury, (n, %) 25 (39.68) 13 (18.57) 0.007* 25 (45.45) 10 (17.86) 0.002* 
RS2470152 genotype, (n, %) 
   CC 
   TC 
   TT 
 
11 (18.33) 
36 (60.00) 
13 (21.67) 
 
22 (37.29) 
22 (37.29) 
15 (25.42) 
0.028*  
13 (25.00) 
30 (57.69) 
9 (17.31) 
 
12 (25.00) 
18 (37.50) 
18 (37.50) 
0.053 
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Table 9. Demographic and Clinical Variables by T1 and T2 TNFα 
 T1  T2  
Variables TNFα 
Above 
Median 
(n=72) 
TNFα Below 
Median (n=71) 
p-value TNFα Above 
Median (n=62) 
TNFα Below 
Median (n=62) 
p-value 
Age (Mean, SE) 41.92 (2.08) 36.77 (1.81) 0.099 38.23 (2.00) 36.98 (2.05) 0.631 
Sex (men, %) 57 (79.17) 58 (81.69) 0.704 50 (80.65) 50 (80.65) 0.999 
Race, (n, %) 
   White 
   Black  
 
70 (97.22) 
2 (2.78) 
 
63 (90.00) 
7 (10.00) 
0.074  
60 (96.77) 
2 (3.23) 
 
54 (88.52) 
7 (11.48) 
0.079 
Best in 24 hour GCS (Median, IQR) 7 (5-8) 7 (6-8) 0.149 7 (6-8) 7 (6-8) 0.483 
ISS (Mean, SE) 35.42 (1.18) 31.65 (1.27) 0.069 34.73 (1.43) 33.25 (1.25) 0.639 
Non-head ISS (Mean, SE) 15.48 (1.39) 10.60 (1.26) 0.006* 14.16 (1.50) 11.27 (1.30) 0.181 
Length of Hospital Stay (Mean, SE) 19.36 (1.52) 20.71 (1.55) 0.460 21.55 (1.74) 21.42 (1.58) 0.828 
Mechanism of Injury, (n, %) 
   MVA 
   Motorcycle 
   Fall 
   Other 
 
29 (42.65) 
16 (23.53) 
15 (22.06) 
8 (11.76) 
 
34 (48.57) 
13 (18.57) 
15 (21.43) 
8 (11.43) 
0.878  
29 (49.15) 
13 (22.03) 
12 (20.34) 
5 (8.47) 
 
28 (27.46) 
13 (22.03) 
10 (16.95) 
8 (13.56) 
0.827 
CT injury type, (n, %) 
   SDH 
   SAH 
   IVH 
   EDH 
   DAI 
   Contusion 
 
45 (63.38) 
53 (74.65) 
18 (25.35) 
11 (15.49) 
20 (28.17) 
31 (43.66) 
 
50 (70.42) 
45 (63.38) 
21 (29.58) 
7 (9.86) 
19 (26.76) 
27 (38.03) 
 
0.373 
0.147 
0.573 
0.313 
0.851 
0.495 
 
43 (69.35) 
49 (79.03) 
21 (33.87) 
6 (9.68) 
15 (24.19) 
30 (48.39) 
 
 
34 (54.84) 
38 (61.29) 
15 (24.19) 
8 (12.90) 
25 (40.32) 
21 (33.87) 
 
 
0.096 
0.031 
0.235 
0.570 
0.055 
0.100 
Splenic injury, (n, %) 8 (11.11) 5 (7.04) 0.397 8 (12.90) 4 (6.45) 0.224 
Abdominal injury, (n, %) 28 (45.16) 18 (27.27) 0.035* 24 (42.11) 18 (33.96) 0.380 
Thoracic injury, (n, %) 22 (35.48) 15 (22.73) 0.112 22 (38.60) 11 (20.75) 0.041* 
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4.4.2 Demographic and Clinical Variables by Mortality Status 
 The clinical and demographic variables by 6-month mortality status are provided in 
Table 10. The average age for non-survivors was significantly higher than survivors (p=<0.001). 
Non-survivors had lower GCS scores compared to survivors (p=0.028). There also was a 
significant difference between survivors and non-survivors with respect to mechanism of injury 
(p=<0.001). Individuals with contusion (p=0.007) and SDH (p=0.092) were more likely non-
survivors, and individuals with DAI were more likely survivors (p=0.004). There was a trend 
between rs2470152 genotype and mortality status (p=0.099), with individuals with TC genotype 
more often non-survivors. 
Table 10. Demographic and Clinical Variables by Mortality Status 
Variable Non-Survivors 
(n=48) 
Survivors (n=109) p-value 
Age (Mean, SE) 51.08 (2.29) 33.54 (1.35) <0.001 
Sex (men, %) 35 (72.92) 92 (84.40) 0.092 
Race, (n, %) 
   White 
   Black  
   Other 
 
45 (95.74) 
2 (4.26) 
0 (0) 
 
99 (91.67) 
8 (7.41) 
1 (0.93) 
0.607 
Best in 24 hour GCS (Median, 
IQR) 
6 (5-7) 7 (6-8) 0.028 
ISS (Mean, SE) 33.90 (1.48) 33.78 (1.00) 0.655 
Non-head ISS (Mean, SE) 14.30 (1.79) 12.89 (1.06) 0.558 
Length of Hospital Stay (Mean, 
SE) 
12.53 (1.34) 23.89 (1.23) <0.001 
Mechanism of Injury, (n, %) 
   MVA 
   Motorcycle 
   Fall 
   Other 
 
16 (35.56) 
8 (17.78) 
18 (40.00) 
3 (6.67) 
 
56 (53.33) 
23 (21.90) 
12 (11.43) 
14 (13.33) 
<0.001 
CT injury type, (n, %) 
   SDH 
   SAH 
   IVH 
   EDH 
   DAI 
   Contusion 
   Other 
 
36 (75.00) 
35 (72.92) 
12 (25.00) 
9 (18.75) 
6 (12.50) 
27 (56.25) 
4 (8.33) 
 
66 (61.11) 
71 (65.71) 
30 (27.78) 
13 (12.04) 
38 (35.19) 
36 (33.33) 
5 (4.63) 
 
0.092 
0.375 
0.718 
0.266 
0.004 
0.007 
0.360 
Splenic injury, (n, %) 4 (8.33) 11 (10.09) 0.730 
Abdominal injury, (n, %) 15 (36.59) 38 (39.18) 0.775 
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4.4.3 Cross-lagged Panel Model 
E2 and TNFα were log transformed at T1 and T2 to account for right skewedness. The 
cross-lagged panel is provided in Figure 8, focusing on primary paths between E2 and TNFα at 
T1 to T2. Paths between fixed effects confounders and E2 and TNFα (not shown in Figure 8) at 
T1 were as follows: older age was not associated with higher E2 at T1 (p=0.598), but was 
significantly associated with higher E2 at T2 (β=0.010, p=0.046). Though not meeting a 
statistical threshold, age tended to be associated TNFα at T1 (β=0.009, p=0.078), but not TNFα 
at T2 (p=0.936). GCS was significantly associated with E2 at T1 (β=-0.093, p=0.036), but not at 
T2 (p=0.304). GCS was marginally associated, but not statistically significant, with TNFα at T1 
(β=-0.064, p=0.090), but not at T2 (p=0.255). RS2470152 genotype was not associated with E2 
at T1 or T2 or TNFα at T1 or T2 (all comparisons p>0.10). 
 
Table 10 Continued 
Thoracic injury, (n, %) 10 (24.39) 30 (30.93) 0.439 
RS2470152 genotype, (n, %) 
   CC 
   TC 
   TT 
 
5 (13.89) 
22 (61.11) 
9 (25.00) 
 
25 (28.74) 
36 (41.38) 
26 (29.89) 
0.099 
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Figure 8. Fitted Cross-Lab Panel 
 
 
The autoregressive path between E2 at T1 and E2 at T2 was statistically significant 
(β=0.901, p=<0.001), after adjustment for covariates. Likewise, the autoregressive path between 
TNFα at T1 and TNFα at T2 was significant (β=0.602, p=<0.001), after adjustment for 
covariates. The significance of the autoregressive paths indicate stability in E2 and TNFα with 
time. The cross-lag path between E2 at T1 and TNFα at T2 was statistically significant (β=0.227, 
p=0.002), as was the path between TNFα at T1 and E2 at T2 (β=0.236, p=0.018). The 
significance of both cross-lag paths indicate an independent relationship between the two 
variables over time. 
4.4.4 Survival Analysis 
The unadjusted and covariate-adjusted Cox proportional hazards model for E2 and TNFα 
at T1 and T2 is provided in Tables 4a and 4b, respectively. At T1, E2 was significantly 
associated with risk for mortality, such that each unit increase in ln(E2) was associated with an 
82% increased risk for mortality, after adjustment for covariates (aHR=1.816, 95% CI: 1.143, 
2.885). However, E2 at T2 was not significantly associated with risk for mortality (aHR=0.905, 
**:p-value <0.01;  
*: p-value <0.05 
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95% CI: 0.558, 1.470; p=0.012). TNFα at T1 was associated, though not statistically significant, 
with risk for mortality; a unit increase in ln(TNFα) was associated with a 46% increased risk for 
mortality (aHR=1.464, 95% CI: 0.987, 2.171; p=0.058). TNFα at T2 was significantly associated 
with mortality risk, such that one unit increase in ln(TNFα) was associated with a 2.5 times 
increased risk for mortality (aHR=2.545, 95% CI: 1.396, 4.639; p=0.002). There was no 
significant interaction in the effects of E2 by sex at either T1 (p=0.475) or T2 (p=0.870) (data not 
shown). 
The Harrell’s Concordance Statistic for the unadjusted T1 and T2 E2 and TNFα models 
were 0.707 and 0.696, respectively. Adjusting for age improved model fit to 0.790 and 0.756, 
respectively. Adding in clinical variables (GCS and CT abnormalities) increased the model fit to 
0.836 and 0.801, respectively. The fully adjusted model, adding rs2470152 genotype, had a 
model fit at T1 and T2 of 0.836, and 0.820, respectively, indicating strong model fit overall. 
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Table 11. Cox Proportional Hazards Regression of TI Epoch (1st 72 hours post-injury) 
  Model 1£ Model 2§  Model 3¥  Model 4€  
  Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
ln(E2) 
ln(TNFα) 
Harrell’s 
Concordance 
Statistic 
1.839 (1.305, 2.590) 
1.556 (1.067, 2.270) 
0.707 
<0.001* 
0.022* 
1.743 (1.218, 2.495) 
1.545 (1.033, 2.310) 
0.790 
0.002* 
0.034* 
1.800 (1.152, 2.814) 
1.438 (0.997, 2.073) 
0.836 
0.010* 
0.052 
1.816 (1.143, 2.885) 
1.464 (0.987, 2.171) 
0.836 
0.012* 
0.058 
*: statistically significant at p<0.05 
£: Model 1: Unadjusted  
§: Model 2: Adjusted for Age only 
¥: Model 3: Adjusted for Age and Clinical Variables (Glasgow Coma Scale and CT abnormalities: Contusion, Subdural hematoma, Diffuse Axonal Injury) 
€: Model 4: Adjusted for Age, Clinical Variables, and rs2470152 genotype 
 
 
Table 12. Cox Proportional Hazards Regression of T1 Epoch (lst 72 hours post injury) 
  Model 1£ Model 2§  Model 3¥  Model 4€  
  Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
ln(E2) 
ln(TNFα) 
Harrell’s 
Concordance 
Statistic 
1.356 (0.912, 2.016) 
1.693 (1.026, 2.793) 
0.696 
0.133 
0.039* 
1.238 (0.836, 1.832) 
1.705 (1.053, 2.760) 
0.756 
0.287 
0.030* 
1.111 (0.703, 1.756) 
2.167 (1.239, 3.789) 
0.801 
0.651 
0.007* 
0.905 (0.558, 1.470) 
2.545 (1.396, 4.639) 
0.820 
0.687 
0.002* 
*: statistically significant at p<0.05 
£: Model 1: Unadjusted  
§: Model 2: Adjusted for Age only 
¥: Model 3: Adjusted for Age and Clinical Variables (Glasgow Coma Scale and CT abnormalities: Contusion, Subdural hematoma, Diffuse Axonal Injury) 
€: Model 4: Adjusted for Age, Clinical Variables, and rs2470152 genotype 
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4.5 DISCUSSION 
 The physiological response to TBI is widespread and spans neurological and non-
neurological systems. Following severe trauma, two of the body’s stress regulators, the HPA axis 
and SNS, are triggered to drive the systemic response to injury. An overactive systemic response 
to TBI increases the risk for acute mortality, as a majority of deaths from TBI are non-
neurological in etiology.101,102 Yet, past studies in TBI populations have primarily focused on 
brain-specific biomarkers. The present study provides evidence that peripheral biomarkers, 
TNFα and E2, are inter-related and relevant to survival after severe TBI. 
It is well-documented that TNFα in the brain is produced from activated microglia, and 
acts as a mediator of the neuroinflammatory response to TBI.79,91,189,190 However, the systemic 
role of TNFα is more multi-faceted in the context of TBI. In response to trauma, the SNS 
facilitates an acute phase hepatic response that contributes to an increase in peripheral 
inflammation.176,177,191 Serum E2 is a systemic biomarker that we have previously documented to 
increase in both sexes after severe TBI.96 TNFα in the periphery directly impacts the extra-
gonadal production of E2 by serving as a transcription factor in adipose tissue.93,118–120,180,181 
Also, peripheral E2 propagates systemic inflammation, including TNFα, by acting as a reuptake 
inhibitor of norepinephrine in lymphoid tissue that directly causes the SNS response to injury to 
amplify.87,121  
Our findings from this study support our hypothesis that E2 and TNFα are significantly 
related over time in the first six days following TBI. This finding suggests that peripheral 
inflammatory and hormone networks are biologically inter-related in the acute phases following 
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TBI, which likely represents a pathological cascade that is relevant to survival after severe TBI. 
Our results show that both E2 and TNFα are significant mortality markers in different time 
epochs in the first five days after severe TBI. In the first 72 hours, E2 is associated with mortality 
risk, but its levels are not independently associated with mortality risk in second 72 hours after 
TBI. TNFα, in contrast, is a highly significant mortality marker in the second 72 hours after TBI, 
and modestly associated with mortality in the first 72 hours.  
The results from this study add to the existing body of clinical evidence of the lethal 
consequences of excessive systemic E2 and TNFα. Two independent studies in populations of 
intensive care unit patients, observed that elevations in serum TNFα were associated with 
incident sepsis/septic shock and in-hospital mortality.115,192 In a clinical study in a general trauma 
population, Zolin and colleagues121 determined that elevations in systemic E2 at 24 hours post-
injury were associated with an increased odds for multiple organ failure. Two other studies in 
populations of surgical and trauma patients, determined that systemic E2 is a strong predictor of 
mortality from trauma.193,194 In TBI, previous studies by Wagner and colleagues have shown that 
peripheral E2,96 along with its precursors E1195 and Androstenedione,196 are potent mortality 
markers. A potential mechanism for observed harmful effects of systemic E2 after trauma could 
be through its vasodilatory actions, promoting harmful nitric oxide and hydrogen sulfide 
pathways.97–100 Converging evidence from clinical studies across patients with varied etiologies, 
suggests that the E2 and TNFα response represents broadly the pathophysiological response to 
severe trauma or critical illness, and correspondingly, elevations in systemic E2 and TNFα 
concentrations are lethal.    
The results of this study are particularly timely in the field considering the recent findings 
of two large phase III trials for progesterone treatment for TBI population.163,164 Crucially, 
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progesterone is the biological precursor of E2 in the steroidogenesis pathway. Our findings from 
this study indicate that individuals with higher endogenous E2, and concurrently its extra-
gonadal transcription factor TNFα, are at great risk for mortality after severe TBI. High baseline 
levels of these two systemic biomarkers may explain, in part, the null findings observed in the 
progesterone trials; however, this hypothesis needs to be formally tested.165,166  
It is important to discuss the tremendous initial promise of Progesterone as a 
neuroprotectant. It demonstrated appreciable neuroprotective benefits in several experimental 
TBI studies conducted over multiple decades.165,166,197–200 Though, the results did not translate to 
human TBI. One reason could be that experimental TBI in animals does not exactly mirror what 
is observed clinically with hospitalized patients with severe TBI. For instance, animals are not 
comatose, do not require intubation, and are not as prone as humans to systemic or critical 
illness. Clinical observational studies have documented the high rates of non-neurological deaths 
in severe TBI populations.101,102 It is possible that (for some) the contribution of the acute 
systemic response to severe trauma is a larger driver of survival than pathophysiological changes 
in the CNS. We propose that a baseline assessment of an individual’s E2 and TNFα, along with 
clinical and demographic variables like age and GCS, are important to the contextualize baseline 
risk for mortality after severe TBI. This may have specific utility to inform participant inclusion 
into clinical trials. Individuals with a high baseline risk may not be strong candidates for 
neuroprotective clinical trials, as they are at high risk for mortality independent of any treatment 
received. For these individuals, concerted efforts should be focused on preventing or controlling 
major systemic compromise to prevent mortality. In contrast, individuals with low or moderate 
baseline risk for mortality due to major systemic compromise would be more appropriate 
candidates for inclusion into neuroprotective clinical trials.   
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In this study, we observed extracerebral trauma is a particularly strong risk factor for 
systemic increases in E2 and TNFα. Individuals with concurrent thoracic, abdominal, and splenic 
injuries had higher levels on average of E2 and TNFα. It is likely that extracerebral trauma 
exacerbates the secondary systemic inflammatory response. We also observed that rs2470152 
genotype and older age were associated with elevated E2; however, interestingly, we did not see 
differences in E2 by sex, suggesting the elevations E2 concentrations post-TBI are primarily 
derived from extra-gonadal sources. 
A cross-lag panel analysis was utilized in this manuscript to characterize E2 and TNFα 
relationships over the first week. Through the simultaneous modeling of autoregressive and 
cross-lags paths, this statistical methodology allows for the examination of longitudinal 
relationships of multiple variables. Historically, this method has been principally applied in the 
developmental and social science literature;185,186 however, we argue it has tremendous utility in 
TBI biomarkers research to aid in the study of relationships between markers across time. Such 
type of statistical modeling can be used, in conjunction with hypothesized theories and empirical 
results from experimental studies, to better understand longitudinal patterns and feedback 
relationships between biomarkers of interest after TBI.  
There are study limitations that should be discussed. Our primary analysis consisted of 
biomarkers averaged over the first 72 hours (T1) and second 72 hours (T2). Because of missing 
data with conflicts with clinical care, we were unable to have more granularity in our data (e.g. 
daily levels). In addition, though the cross-lag approach nicely shows the inter-relatedness 
between E2 and TNFα across T1 and T2, even after the adjustment for confounders, the study 
design is still a human observational study in an acute hospital setting; so we cannot conclude 
that the observed relationships are causal. Further, this study focuses on TNFα as the primary 
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systemic inflammatory marker and extra-gonadal transcription factor; however, there is evidence 
to suggest that cortisol201 and interleukin-6202 are also known transcription factors for E2, and 
may also contribute to propagation of the systemic pathophysiological response to injury. Also, 
we adjusted for the confounders of age, GCS, CT abnormalities (contusion, SDH, DAI), and 
rs2470152); however, it is possible other unmeasured confounding could alter the observed 
effect estimates for the cross-lag and survival analysis models. Finally, this study was performed 
in a cohort with severe TBI, and thus the utility of E2 and TNFα as prognostic indicators of 
mortality are not necessarily generalizable to those with less severe injuries; however recent 
studies have noted differences in neurologic and quality-of-life outcomes by sex hormones in 
mild TBI populations.203  
In conclusion, the results from this study provide intriguing evidence to support the 
hypotheses that the peripheral inflammatory and hormone markers, E2 and TNFα, have a 
positive feedback relationship in the first week following severe TBI, and both biomarkers have 
prognostic value as indicators of mortality risk after injury. These biomarkers may be TBI 
relevant for both research and clinical purposes to gauge baseline risk for systemic compromise 
and mortality. Future experimental TBI studies should consider ways to simultaneous model 
systemic compromise or septic shock204 in addition to TBI-alone to more appropriately mirror 
severe TBI clinical conditions. Additionally, future experimental studies should examine the 
potential benefits of aromatase- and TNFα-inhibitors, as well as adrenergic blockage therapies. 
Future clinical studies would benefit from prospectively monitoring E2 and TNFα daily and the 
subsequent risk for major systemic compromise and NNOD.   
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5.0  GENERAL DISCUSSION 
5.1 SUMMARY OF RESULTS 
Clinicians across the care continuum that treat patients with serious brain injuries have 
two overarching goals: 1) avoid acute mortality; and 2) assuming acute survival, avoid long-term 
disability. My dissertation addresses these two topics by studying the effect of acute factors on 
survival and long-term recovery following moderate-to-severe TBI. I focused on two factors, 
which are not primarily brain-related, but rather secondary systemic components: pneumonia and 
peripheral inflammation and hormone levels. In the first aim of my dissertation, I describe the 
methods we used to create a novel dataset spanning early to chronic phases after TBI. The 
second and third aims are original prospective cohort studies examining acute factors associated 
with long-term disability and survival. The results indicated that the identified non-neurological 
factors are highly relevant for survival and long-term disability.  
Aim 1 describes the probabilistic matching methodology used to merge two large 
databases, the NTDB and TBIMS. These two datasets uniquely contain variables that are largely 
non-overlapping across the time course of TBI; the NTDB contains extensive data on acute care 
hospitalizations; however, has little information after a patient is discharged. In contrast, the 
TBIMS is a rehabilitation database that has detailed information collected from when a patient is 
admitted to rehab, and it also has subsequent long-term follow-up until death. Individuals 
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eligible to be enrolled in the TBIMS were admitted to a Level I trauma center for their acute 
care, meaning they were also represented in the NTDB. However, due to the lack of co-
registration of participants between the NTDB and TBIMS, there are not common identifiers 
between databases, requiring probabilistic matching to match participants between datasets using 
a series of common data elements. We first developed142 and validated143 the algorithm using 
data collected at two sites where we also simultaneously identified deterministic pairs. Aim 1 of 
the dissertation provides detailed information on the validation of this algorithm in a single 
clinical site. The developed algorithm was applied to the entire NTDB and TBIMS to arrive at a 
matched cohort of n=4022.   
Aim 2 of this dissertation leverages the merged NTDB-TBIMS database created in Aim 1 
to test the hypothesis that HAP is associated with long-term disability after moderate-to-severe 
TBI. The merged cohort was restricted to n=3712 adults with moderate-to-severe TBI injured 
between 1998-2013. The primary outcome was the GOS-E, a measure of global disability 
commonly used in TBI clinical trials and observational studies. The secondary outcomes 
included metrics of hospital resource utilization, such as length of stay, efficiency during 
rehabilitation, and rehospitalization. We observed a HAP incidence rate of 32.7%. Clinical 
factors associated with HAP included greater brain injury severity, extra-cerebral injury severity, 
mechanism of injury, significant thoracic injuries, being on a ventilator, an intraventricular 
hemorrhage, and subarachnoid hemorrhage. We observed that individuals with HAP had a 34% 
increased risk for prolonged global disability compared to individuals without HAP. For the 
secondary objective, we observed that individuals with HAP had over a two-week longer acute 
and rehabilitation LOS (combined) compared to individuals without HAP, independent of 
confounders like age and brain injury severity.  
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The results gathered from this study provide compelling evidence that the effects of HAP 
extend beyond the infection period itself and are an independent risk factor for prolonged chronic 
disability. The biological rationale of this relationship is potentially explained through an 
inflammatory hypothesis: individuals with TBI that suffer systemic infections during their acute 
hospitalization prime their system to devolve into a chronic inflammatory state. In a previous 
study I was involved in,86 among a cohort of n=87 adults with severe TBI, we determined that 
individuals with a greater number of hospital complications had significantly greater chronic 
inflammatory load in the first 3 months following injury, even after patients were presumably 
treated for their infections. Individuals with HAP more often have fever, hypotension and 
hypoxemia, all of which aggravate the biological response to TBI.205 It is likely that individuals 
with HAP were more likely to continue to have prolonged pathological effects from their injury 
that explain long-term disability.  
Aim 3 of my dissertation focused on systemic pathophysiology after injury. Even though 
TBI is a primary injury to the brain, this study shows the biological effects are not confined to 
neurological processes. In response to a traumatic injury, two main “stress” pathways are 
triggered in the brain, the SNS and HPA axis, which exert effects throughout the body. The 
output of the HPA-axis is the adrenals, which releases the stress hormone cortisol upon 
activation, which has known anti-inflammatory properties under certain conditions. Activating 
the SNS results in a downstream trigger of the acute phase hepatic response, producing pro-
inflammatory cytokines like TNFα. Increases in TNFα promote the synthesis of the sex 
hormone, E2, at extra-gonadal sites.93–95 E2 has potent pro-inflammatory effects that contribute 
to increases in peripheral cytokines. Elevations in E2 and TNFα could be the product of a 
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reciprocal biochemical pathway that represents increased risk for non-neurological organ 
dysfunction.  
In Aim 3, we studied n=157 adults with severe TBI and collected serum samples of 
TNFα and E2 in the first five days after injury. To test the hypothesis that a positive feedback 
loop exists between peripheral TNFα and E2 production acutely after severe TBI, we conducted 
a cross-lag analysis. Our results showed that TNFα and E2 were significantly related over time 
across early and delayed time periods acutely following TBI. We also observed that TNFα and 
E2 were significant prognostic indicators of risk for mortality in early phase after TBI, and 
TNFα’s effects on mortality were sustained into the delayed period in the second 72 hours after 
injury. One potential biological explanation of the relationship is that these biomarkers represent 
an increased likelihood for death from systemic complications and non-neurological organ 
dysfunction.102,121 The findings from this study are important to understand baseline risk for 
mortality after severe TBI, and may be applied, for example, to stratify patients for inclusion in 
clinical trials by baseline risk. 
5.2 PUBLIC HEALTH IMPACT 
Each year, 2.5 million Americans suffer a TBI.125 Moderate-to-severe TBI is a major 
cause of death, especially among young adults,126,159 and a majority of those that survive their 
initial injuries, live with lifelong disabilities. This accounts for an estimated 5 million Americans 
living with chronic TBI disability.2,42,206 The economic burden of chronic disability is 
considerable both from direct medical costs and indirect cost from lack of productivity. Previous 
studies have estimated that an acute TBI hospitalization is over $4,000 per day.207   
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Brain injury is different from orthopedic injury to other parts of the body where 
individuals have an expected recovery timeline, and most return to pre-injury function after some 
structured period of rehabilitation. In contrast, individuals with moderate-to-severe TBI have an 
extended recovery period, which for some individuals results in a lifetime of disability. This 
striking difference in recovery between brain and orthopedic injuries is the consequence of great 
individual differences in the response of the brain. TBI researchers in the basic and clinical 
sciences are thus charged with characterizing this heterogeneity to inform personalized treatment 
regimens. 
TBI Research is interdisciplinary and spans neuroscience (e.g. animal models of TBI), to 
many clinical disciplines (e.g. emergency medicine, critical care medicine, neurosurgery, trauma 
surgery, and rehabilitation), to public health (e.g. injury prevention, neuroepidemiology). In my 
doctoral training, I have had some exposure to these different disciplines within TBI research; 
my degree focus is in neuroepidemiology, and I also work closely with TBI physicians from 
multiple specialties. One striking conclusion I made is there is a great deal of silo’d research 
within medical fields in TBI. For instance, trauma researchers have not historically examined 
outcomes after acute inpatient hospitalization. From a rehabilitation perspective, research largely 
begins when a patient enters rehab and they are followed for months and years to track 
integration back into the community. Historically, rehabilitation researchers have seldom 
considered the effect of acute hospital factors on long-term recovery. Silo’d research may be 
caused by many factors; trauma and rehabilitation researchers often do not attend the same 
scientific conferences and meetings, and as a result, few collaborations have existed between the 
fields. The result is a dearth of available large studies that span from early to late time phases of 
injury. The identification of this “gap” by my mentor Dr. Wagner and myself, prompted Aim 1 
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of my dissertation to merge two large databases: the NTDB and TBIMS. By doing so, we created 
an infrastructure to study the long-term effects of acute care variables, like hospital 
complications, admissions vital signs, extracerebral trauma, and surgical procedures. The 
bridging of these field offers the opportunity to ask new questions that more completely consider 
the TBI life-course.  
The downstream consequences of poor integration between disciplines is not restricted to 
research, but has profound implications for the clinical care of patients with TBI. There are data 
to suggest that a significant proportion of individuals with a TBI requiring a hospitalization do 
not receive rehabilitation care and services, with racial minorities208 and uninsured populations209 
disproportionately not receiving rehab services. Disparities in the receipt of rehabilitation is 
likely greater than the receipt of acute care services, like neurosurgery and critical care medicine, 
where the acuity and urgency of injuries necessitate immediate care for survival. In contrast, 
payors must balance the potential benefits gained from rehabilitation to the high costs of care, 
when patient survival is primarily not in the balance. One low hanging solution to address this 
disparity is to emphasize early rehabilitation consultation and intervention during acute care 
itself, which has begun being implemented in many leading academic health centers. Needham 
and Korupolu210 proposed a Rehabilitation Quality Improvement Model in which Rehabilitation 
clinicians (e.g. Physiatrists, Physical Therapists, Occupational Therapists, Speech-Language 
Therapists) work with critically ill patients while they are still in the critical care unit. This 
program showed benefits by decreasing in the average hospital length of stay and increasing 
early mobility. Another study in a TBI population conducted by Wagner and colleagues211 
showed that Rehabilitation consultation in acute care resulted in better functional recovery and 
shorter length of stay. Clinically, here in the University of Pittsburgh Medical Center, Dr. 
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Wagner leads a brain injury medicine consult service where she facilitates successful transition 
of care for acutely injured severe TBI patients. Rehabilitation services include: early 
neurostimulant use, restorative sleep, agitation management, and control over SNS overactivity. 
The goal of building bridges between acute care and rehabilitation has gained traction in 
recent years. The American College of Surgeons (ACS) and American Congress of 
Rehabilitation Medicine (ACRM), two of the largest acute care and rehabilitation organizations 
respectively, are in active discussions to blend clinical and research efforts between acute care 
trauma surgeons and rehabilitation for TBI, including through database activities that would 
allow for shared data collection. Clinically, there are discussions within these groups of how to 
modify existing frameworks, such as the Needham’s model,210 to fit the needs of TBI 
populations. The ultimate long-range plans of such clinical initiatives are to increase access to 
rehabilitation for all patients with TBI.  
From a research perspective, the leadership within these organizations specifically 
identified the NTDB-TBIMS merged database as an exemplar of research successes in bridging 
the trauma and rehabilitation fields. In fact, our expertise is being sought to develop a path 
forward to prospectively collect linked data between the NTDB-TBIMS through deterministic 
means. Specifically, Dr. Wagner and I plan to hold meetings with key stakeholders in the trauma 
and rehabilitation community nationally to develop and implement this plan. One tangible “boots 
on the ground” step could be to identify trauma and rehabilitation partners at each TBIMS 
clinical site, and determine ways to integrate trauma registry data into prospective data 
collection. The system of prospective data collection in concert between trauma and 
rehabilitation centers may forge opportunities to not only increase the quality of the merged 
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database, but also to develop new research and clinical care partnerships between trauma and 
rehabilitation colleagues for years to come. 
5.3 FUTURE RESEARCH 
My vision cast for the future direction for the field of TBI research and clinical care is to 
conduct more cross-cutting studies across the TBI disability continuum, from early to long term 
periods after injury. The merged NTDB-TBIMS dataset is one exemplar of the integration of 
acute and rehabilitation factors, though, it remains only one component. In Figure 9, I illustrate 
how I conceptualize the TBI disability clinical and research continuum. Prior to incident injury, 
individuals with TBI may have an existing physical or mental health disease burden that could 
complicate recovery. In a previous study I co-authored,6 we determined that there are three main 
clusters of comorbidities present among middle aged-to-older adults with TBI: 1) hospital 
complications, 2) chronic diseases, and 3) substance abuse disorders. From data in a follow-up 
study in review, we find that greater comorbidity burden is a risk factor for poorer recovery 
during the first year after TBI. Additionally, work from my Master’s degree thesis found that 
presence of pre-injury depression is associated with poorer affective/behavioral symptoms, 
cognition, and quality of life in the first three months after TBI.212 These studies together suggest 
that an individual’s pre-injury characteristics are important for post-injury recovery. In my 
postdoctoral training plan, I will continue to delve into the concept of a TBI disability continuum 
by examining late-life and post-mortem analyses of brain health. As a long-term career goal, I 
hope to design and conduct studies across the continuum, working alongside clinicians and 
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researchers spanning trauma and rehabilitation fields, to identify risk factors to target for 
improving long-term recovery.  
 
Figure 9. TBI Disability Clinical & Research Continuum 
Spanning from left to right over time, the TBI Disability Clinical & Research Continuum spans five distinctive but 
interconnected phases, which are as follows: 1) Pre-injury factors: Comorbid disease burden, which could include chronic 
conditions, substance abuse disorders, or mood and behavioral illnesses; 2) Acute-to-Subacute factors: The early 
pathophysiological response to TBI, results in perturbations to brain-based biomarkers, peripheral biomarkers. Acutely, clinical 
factors may also complicate the recovery course, such as hospital infections, including pneumonia. Clinical interventions, 
including craniotomy and craniectomy, directly impact acute survival; 3) Subacute-to-Chronic factors: Patients begin to depart 
from a state of post-traumatic amnesia; TBI-related impairments exist, including: seizures, cognitive impairment, 
mood/behavioral dysfunction, headache, fatigue, sleep disturbance, and pain; 4) Lifetime factors: A subset of patients live with 
prolonged TBI impairments and disability. Data show evidence for an increased risk for neurodegeneration and premature death 
after TBI compared to individuals without TBI; 5) Post-Mortem: Neurodegeneration in post-mortem brain of patients with TBI. 
 
5.3.1 TBI is a global health problem requiring worldwide research 
Importantly, TBI is not only a problem here in the United States, but a significant 
worldwide public health concern that is among the top 15 causes of death in all age groups less 
than 60 years old. It is also the single leading cause of disability in people under 40 years of age 
in the world.213 The World Health Organization (WHO) estimates that motor vehicle accidents, 
which account for 60% of TBI in all parts of world, will be the third leading cause of disability 
and death for all ages worldwide by 2020.214 The greatest burden of TBI is in low- and middle-
income countries, which account for 90% of injury-related deaths in these populations. However, 
research is immensely lacking in developing populations.215 An important future direction for the 
TBI field is testing the external validity of clinical trials conducted in the United States and other 
developed countries in lower- and middle-income countries to ensure interventions work in a 
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variety of clinical settings worldwide. It is imperative to find effective treatments to lower the 
mortality and morbidity burden of TBI around the world. 
5.4 CONCLUSION 
Though TBI is now considered by most experts in the field as a chronic disease,216 the 
etiology of TBI, and associated complications, make it more heterogenous compared to many 
chronic diseases. That is, TBI can occur among individuals of any age, sex, race, health status, 
socioeconomic status, or genetic makeup, which makes it one of the most wide-ranging chronic 
diseases facing society today worldwide. The tremendous heterogeneity of TBI makes it difficult 
to study. For example, the most recent large RCT in TBI, the Progesterone for Traumatic Brain 
Injury Experimental Clinical Treatment trial, had an age range from 17 to 94.163 The unfortunate 
reality is that over 30 large clinical trials for TBI have failed to show neuroprotective benefits.160 
In the extensive effort to find a single drug that works for all patients with TBI, the field is 
currently without a single effective neuroprotective drug for anyone.   
This dissertation has several implications that add to the field. The merged database 
generated from methods outlined in Aim 1 is an important infrastructure from which to conduct 
novel research that spans trauma and rehabilitation. The results from Aim 2 indicate that every 
effort should be made by clinicians to prevent HAP after TBI, as it represents a known 
modifiable risk factor that can impact the long-term prognosis for patients with moderate-to-
severe TBI. From Aim 3, the identification of objective biomarkers in the initial days following 
TBI to predict risk for mortality have important implications, as biomarkers are a means to 
promote a more personalized medicine approach to TBI clinical practice and research. There is a 
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movement away from clinical injury severity measures, such the GCS, as prognostic markers to 
identify at-risk patients. Since many patients with moderate-to-severe TBI have prolonged 
periods of unconsciousness and post-traumatic amnesia, having early objective molecular 
measures that do not rely on patient report are critical to identify patients at-risk for mortality. 
Clinically, this has the potential to alter the way clinicians prioritize certain treatments, such as 
the usage of life-saving procedures. From a research perspective, because of their elevated 
baseline risk for mortality, patients with high concentrations of E2 and TNFα early after TBI 
may not be the best candidates for enrollment future trials focused on neuroprotective strategies. 
Future clinical trials may also benefit from investigation of ways to directly modify E2 and 
TNFα through the use of aromatase and TNF-inhibitors, respectively.  
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APPENDIX: SUPPLEMENTAL TABLES CHAPTER 1 
Supplementary Table 1. Cluster weight differences for true and false matches in the algorithm generation 
and validation sets 
 
 False Match True Match 
Training set   
  Mean (SD) 2.8 (3.9) 14.5 (8.5) 
  Median (IQR) 1.4 (0.6, 3.4) 13.8 (7.9, 19.7) 
  5th percentile 0 2.4 
  90th percentile 7.0 26.0 
Validation set   
  Mean (SD) 4.2 (4.8) 16.0 (9.3) 
  Median (IQR) 2.3 (1.0, 6.1) 15.5 (8.6, 22.2) 
  5th percentile 0 2.2 
  90th percentile 9.4 33.0 
 
Supplementary Table 2. Distribution of selected blocking and matching fields by Tier II matching 
status in the algorithm generation and validation sets 
 
 Total Tier II matched 
Tier II non-
matched P-value
1 
Training set     
N 497 332 165  
Age, mean (SD) 38.6 (17.6) 40.0 (18.0) 36.0 (16.7) 0.016 
GCS eye, mean (SD) 2.4 (1.4) 2.3 (1.4) 2.5 (1.4) 0.345 
GCS motor, mean (SD) 3.7 (2.1) 3.7 (2.1) 3.8 (2.2) 0.346 
GCS verbal, mean (SD) 3.2 (1.6) 3.2 (1.6) 3.4 (1.7) 0.302 
GCS total, mean (SD) 10.8 (4.3) 10.7 (4.2) 11.0 (4.7) 0.282 
SBP, mean (SD) 134.8 (29.1) 134.9 (30.6) 134.5 (25.3) 0.834 
Reparatory rate, mean (SD) 20.2 (6.4) 20.0 (6.7) 20.7 (5.6) 0.306 
LOS, mean (SD) 20.1 (12.5) 20.8 (12.6) 18.7 (12.2) 0.048 
Female, % 30.6 33.1 25.5 0.080 
Race, %2    0.483 
White 78.5 77.7 80.0  
Black 17.9 19.3 15.2  
Asian/Pacific islander 0 0 0  
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Supplemental Table 2 Continued 
 
Hispanic 2.8 2.4 3.6  
Other 0.8 0.6 1.2  
Skull base fracture, % 33.2 31.9 35.8 0.393 
Cranial surgery, % 20.2 20.8 19.2 0.733 
Validation set     
N 544 380 164  
Age, mean (SD) 38.9 (18.3) 39.7 (19.1) 37.1 (16.3) 0.294 
GCS eye, mean (SD) 2.4 (1.4) 2.3 (1.4) 2.5 (1.4) 0.309 
GCS motor, mean (SD) 3.8 (2.2) 3.8 (2.1) 3.7 (2.2) 0.852 
GCS verbal, mean (SD) 3.2 (1.6) 3.1 (1.6) 3.3 (1.5) 0.620 
GCS total, mean (SD) 10.7 (4.3) 10.6 (4.2) 11.0 (4.3) 0.618 
SBP, mean (SD) 136.0 (31.6) 138.4 (31.3) 129.3 (31.4) 0.015 
Reparatory rate, mean 
(SD) 
20.6 (9.8) 20.2 (7.2) 22 (16.1) 0.712 
LOS, mean (SD) 21.4 (14.1) 22.0 (14.8) 19.9 (12.2) 0.191 
Female, % 28.1 26.6 31.7 0.222 
Race, %2    0.881 
White 71.7 71.3 72.6  
Black 22.1 21.8 22.6  
Asian/Pacific islander 1.6 1.6 1.8  
Hispanic 3.9 4.5 2.4  
Other 0.7 0.8 0.6  
Skull base fracture, % 29.4 29.0 30.5 0.718 
Cranial surgery, % 20.4 21.4 18.2 0.470 
1 Kruskal-Walis test for continuous variables and chi-square test unless otherwise specified for categorical variables 
  for comparison between matched and non-matched cases 
2  Fisher exact test applied for P-value 
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